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Abstract
Gliomas, the tumors of glial cells, account for 80% of primary malignant brain tumors. In 2011, there were
about 18,300 new cases of maligant gliomas in the United States alone. Patients with glioblastoma
multiforme or anaplastic astrocytoma, the two major types of malignant gliomas, have a median survival
of 14 months or 2 to 3 years, respectively. Therefore novel treatments for malignant glioma are urgently
needed.
A novel series of tetrahydroisoquinoline derivatives with antiglioma activity has been undergoing drug
metabolism/pharmacokinetics (DMPK)-guided lead optimization. EDL-291 was result from structure
modification of last generation compound EDL-155. Its preclinical pharmacokinetics were characterized
in this dissertation project. In male Sprague Daley (SD) rats, after 10 mg/kg intravenous injection, total
body clearance (CL) of EDL-291 was 209 mL/min/kg (CV 23.7%), 39% lower than EDL-155 but still much
higher than rat liver blood flow. 1.2% of dosed EDL-291 was found in urine (fe) over the 24 hr post-dose
period. EDL-291 is stable in whole blood, not accumulated in red blood cells, but susceptible to pulmonary
microsomal metabolism. Thus, extensive lung metabolism is the major contributor of the high CL value.
The volume of distribution of EDL-291 at steady state (Vdss) in SD rats was 32.5 L/kg (CV 46.6%). The
ratio of the EDL-291 brain area under concentration curve (AUC) to plasma AUC between 20 - 180 min
after intravenous injection was 14.0. The brain/plasma AUC ratio at 10 - 180 min after 50mg/kg
subcutaneous injection to C57BL/6J mice was 4.07. The bioavailability (F) of EDL-291 after 40mg/kg oral
gavage in SD rats was 40.4%. Attempts to reduce pulmonary metabolism led to the discovery of EDL-323,
which had a dramatically reduced clearance compared to EDL-291. However, the brain penetration of
EDL-323 was significantly lower than EDL-291. Thus, further structural modifications are required to
achieve both reduced clearance and enhanced brain penetration.
Antigloma activity of EDL compounds was discovered in phenotype screening. A preliminary evaluation of
the effect of EDL-291 on human glioma cell apoptosis machinery was conducted as part of the effort to
elucidate its mechanism of action. After EDL-291 treatment, active caspase-3 and the amount of cleaved
PARP were increased in both U87MG and U-251 cells. In addition, the antiproliferative effect of EDL-291
was partially reversed by a caspase-3/7 inhibitor. However, neither the caspase-8 inhibitor nor caspase-9
inhibitor reversed the apoptotic effect of EDL-291. Decylubiquinone (dUb) can enhance caspase-3
activation as well as antiproliferative effect caused by EDL-291 treatment. Therefore, dUb could be a
candidate companion drug of EDL-291 analogs in treating glioma.
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ABSTRACT
Gliomas, the tumors of glial cells, account for 80% of primary malignant brain
tumors. In 2011, there were about 18,300 new cases of maligant gliomas in the United
States alone. Patients with glioblastoma multiforme or anaplastic astrocytoma, the two
major types of malignant gliomas, have a median survival of 14 months or 2 to 3 years,
respectively. Therefore novel treatments for malignant glioma are urgently needed.
A novel series of tetrahydroisoquinoline derivatives with antiglioma activity has
been undergoing drug metabolism/pharmacokinetics (DMPK)-guided lead optimization.
EDL-291 was result from structure modification of last generation compound EDL-155.
Its preclinical pharmacokinetics were characterized in this dissertation project. In male
Sprague Daley (SD) rats, after 10 mg/kg intravenous injection, total body clearance (CL)
of EDL-291 was 209 mL/min/kg (CV 23.7%), 39% lower than EDL-155 but still much
higher than rat liver blood flow. 1.2% of dosed EDL-291 was found in urine (fe) over the
24 hr post-dose period. EDL-291 is stable in whole blood, not accumulated in red blood
cells, but susceptible to pulmonary microsomal metabolism. Thus, extensive lung
metabolism is the major contributor of the high CL value. The volume of distribution of
EDL-291 at steady state (Vdss) in SD rats was 32.5 L/kg (CV 46.6%). The ratio of the
EDL-291 brain area under concentration curve (AUC) to plasma AUC between 20 - 180
min after intravenous injection was 14.0. The brain/plasma AUC ratio at 10 - 180 min
after 50mg/kg subcutaneous injection to C57BL/6J mice was 4.07. The bioavailability (F)
of EDL-291 after 40mg/kg oral gavage in SD rats was 40.4%. Attempts to reduce
pulmonary metabolism led to the discovery of EDL-323, which had a dramatically
reduced clearance compared to EDL-291. However, the brain penetration of EDL-323
was significantly lower than EDL-291. Thus, further structural modifications are required
to achieve both reduced clearance and enhanced brain penetration.
Antigloma activity of EDL compounds was discovered in phenotype screening. A
preliminary evaluation of the effect of EDL-291 on human glioma cell apoptosis
machinery was conducted as part of the effort to elucidate its mechanism of action. After
EDL-291 treatment, active caspase-3 and the amount of cleaved PARP were increased in
both U87MG and U-251 cells. In addition, the antiproliferative effect of EDL-291 was
partially reversed by a caspase-3/7 inhibitor. However, neither the caspase-8 inhibitor nor
caspase-9 inhibitor reversed the apoptotic effect of EDL-291. Decylubiquinone (dUb) can
enhance caspase-3 activation as well as antiproliferative effect caused by EDL-291
treatment. Therefore, dUb could be a candidate companion drug of EDL-291 analogs in
treating glioma.
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CHAPTER 1.

INTRODUCTION

In 2011, there were more than 248,000 new cases of primary malignant brain
tumors around the world [1], while about 22,000 new cases were in the United States [2].
About 182,000 people [1], including 13,000 Americans [2], died from primary malignant
brain tumors each year. 80% of these tumors are gliomas, while glioblastoma (World
Health Organization [WHO] grade IV) is the most common (Figure 1-1) and also the
most malignant glioma [3]. Under the current standard of care, glioblastoma patients only
have a 14 month life expectancy after diagnosis [4]. For patients with anaplastic
astrocytoma (WHO grade III), another major type of malignant glioma, the life
expectancy is somewhat longer (2–3 years) [5]. New treatment options for malignant
gliomas are urgently needed.
1.1. Gliomas: Status Quo
1.1.1. Epidemiology
According to most recent CBTRUS (Central Brain Tumor Registry of the United
States) report, incidence rate of primary brain tumors was 19.89 per 100,000 person–
years in the USA (2004 - 2008) [3]. According to Surveillance, Epidemiology, and End
Results (SEER) Cancer Statistics Review, the incidence rate of primary malignant brain
tumors is 6.5 per 100,000 person–years in the USA, which suggests that about 22,340
new cases developed in 2011 [2]. The total number of primary malignant brain tumor
deaths for the USA in 2011 is estimated to be 13,110 [2]. As shown in Table 1-1, both
incidence and mortality rates of primary brain tumors in the USA are higher than the
average world rates.
Gliomas (International Classification of Diseases for Oncology, 3rd Edition
[ICD-O-3]: 9380-9384, 9391-9460, 9480) are tumors (Figure 1-1) that arise from
different types of glial cells [3]. As a broad category, gliomas represent 80% of primary
malignant brain tumors in the USA. Gliomas also account for 30% of all primary brain
tumors, which is only slightly less than meningioma (35%). However, only 2% of
meningioma is malignant, while 97% of gliomas are malignant [3]. Incidence rate of
gliomas is 6.04 (5.87 for malignant gliomas) per 100,000 person–years in the USA,
which suggest about 19,000 new cases in 2011 [3].
Based histology and presumed cell of origin, gliomas can be subdivided into
glioblastoma, astrocytoma, oligodendroglioma, ependymoma, and a few more rare
tumors [3]. When these subtypes are counted separately, glioblastoma is the second most
common primary brain tumors, the most common primary malignant brain tumor, and
also most common glioma subtype (53.9%) [3]. Incidence rate of glioblastoma was 3.20
per 100,000 person-years in the USA, which suggests about 10,000 new cases in 2011.
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Figure 1-1.

Distribution of gliomas by histology subtypes

Reprinted from “CBTRUS Statistical Report: Primary Brain and Central Nervous System
Tumors Diagnosed in the United States in 2004-2008.” Source: Central Brain Tumor
Registry of the United States (Hinsdale, IL). Available from: http://www.cbtrus.org/
reports/reports.html [accessed March 12, 2012]. (No permission needed.)

Table 1-1．Primary malignant brain and CNS tumor incidence and mortality
rates in 2008 (age-standardized, per 100,000 person-years)
Gender
Male
Female
Both

Incidence rates
World
USA
3.8
7.6
3.1
5.2
3.5
6.3

Mortality rates
World
USA
2.9
5.3
2.2
3.5
2.5
4.3

Sources: Ferlay J, et al., GLOBOCAN 2008 v2.0, cancer incidence and mortality
worldwide: IARC CancerBase No. 10 [Internet]. Lyon (France): International Agency for
Research on Cancer, 2010. Available from: http://globocan.iarc.fr [accessed Janary 1,
2012]. And Howlader N, et al., SEER cancer statistics review, 1975-2008 [Internet].
Bethesda (MD): National Cancer Institute (USA), 2011. Available from:
http://seer.cancer.gov/csr/1975_2008/ [accessed Janary 1, 2012].

2

When combined together, astrocytomas and glioblastoma account for 76% of gliomas
[3].
A wide variety of factors have been reported to be associated with elevated
glioma risk [6]. According to the 2008 consensus from the epidemiologists in Brain
Tumor Epidemiology Consortium (BTEC) [7], most well-established glioma risk factors
include aging, ionizing radiation exposure and certain rare hereditary syndromes. The
incidence rates of adult glioma increase with older age until age 80 [8]. Data compiled by
CBTRUS shows the incidence rates of glioma in different age groups in the USA during
2004 - 2008 are 2.4 (age 0 - 19), 2.7 (age 20 - 34), 4.1 (age 35 - 44), 6.7 (age 45 - 54),
11.6 (age 55 - 64), 17.3 (age 65 - 74), 19.0 (75 - 84), 11.3 (85 + ) per 100,000
person-years [3]. Ionizing radiation exposure is the only established environmental risk
factor for glioma [6, 9, 10]. Multiple studies show a linear dose–response relationship
between ionizing radiation exposure and glioma risk. A recent study indicates that for
survivors of various childhood cancer in the USA and Canada, exposure to radiotherapy
was associated with significantly increased risks for the development of subsequent
glioma (odds ratio = 6.78), especially when the dose is higher than 30 Gy [11]. An earlier
Israeli study shows that patients who received low dose X-ray therapy (1–6 Gy) in
childhood for tinea capitis (ringworm of the scalp) also have a 2.6-fold increase of risk
for glioma [12]. Another study shows that Japanese atomic bomb survivors have
statistically significant increased risk of glioma (excess relative risk = 0.6 per Sv) [13].
Rare genetic syndromes, such as neurofibromatosis types 1 and 2 (germ-line mutations in
tumor suppressor genes NF1 or NF2), tuberous sclerosis (germ-line mutations in tumor
suppressor gene TSC1 or TSC2), the Li-Fraumeni syndrome (germ-line p53 mutations),
and Turcot syndrome type 1 (biallelic germ-line mutations in DNA mismatch repair
genes hPMS2, hMSH2, or hMLH1), are associated with gliomas [6, 7].
Other established glioma risk factors are male gender, Caucasian race, and
epilepsy/seizures/convulsions [7]. The incidence rate of gliomas is higher in males (7.17
per 100,000 person– years in the USA) than in females (5.08 per 100,000 person–years in
the USA) [3]. When different races/ethnics in the USA are compared, whites have the
highest incidence rate of gliomas (6.2 per 100,000 person–years), followed by Hispanic
and American Indians/Alaska Natives (4.4 and 3.9 per 100,000 person–years,
respectively),while Blacks and Asians/ Pacific Islanders have incidence rates (3.0 and 2.8
per 100,000 person–years)─less than half of the rate of Whites [8]. This is consistent with
the observation that Northern Europe, Australia, Canada, the United States, and New
Zealand, have a primary malignant brain tumor incidence that is much higher than that of
Asian countries, such as the Philippines, India and Japan [10]. Although considered as
risk factors, epilepsy, seizures and convulsions are probably the early symptoms of
glioma [7].
Mutagen sensitivity and family history of gliomas are probable glioma risk factors
[7]. Constructive gene polymorphisms in drug metabolism enzyme genes (GSTs,
CYP2D6 and CYP2E1), DNA repair genes (ERC1, ERCC2, MGMT, and XRCC7),
immune related genes (IL-4RA, IL-13, HLA-B*13, and HLA-B*07-Cw*07), as well as
GLTSCR1, are also considered as possible risk factors. Together with the aforementioned
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rare genetic syndromes, all these factors provide insights on a genetic predisposition to
glioma.
The relationship between radiofrequency electromagnetic fields (non-ionizing
radiation), especially cell phone usage and glioma risk, has been controversial [14]. A
recent Interpone study suggests a 40% increase of glioma risk at the highest exposure
levels (10th decile of recalled cumulative call time, ≥ 1640 h over 10 years), while no
increase was found in other exposure levels [15].
There are also some negative risk factors inversely associated with glioma
incidence, such as high intake of calcium and antioxidants, usage of NSAIDs, history of
allergies or asthma, high serological levels of IgE, history of varicella-zoster virus (VZV)
infection (chickenpox), and presence of anti-VZV IgG [7, 10].
1.1.2. Diagnosis
Patients with glioma can present symptoms including headaches, personality
changes, nausea, vomiting, hemiparesis, sensory loss, visual loss, and seizures [16]. Since
the symptoms are more related to the location of the tumor rather than the pathological
properties, diagnosis of glioma may be delayed until the tumor progresses and invades to
produce clinical symptoms. T1-weighted gadolinium-enhanced magnetic resonance
imaging (MRI) is a standard tool for diagnosis patients with glioma. It is believed that
tumor cells can still be found at 2 cm beyond the enhancing border. Magnetic resonance
spectroscopy (MRS) is commonly used in the clinic to measure metabolic activity, thus
providing important information for monitoring the therapeutic response and early
detection of relapse. In addition, Positron emission tomography (PET) is also being
applied in the clinic in diagnosing gliomas [17].
1.1.3. Current treatment and difficulties
1.1.3.1. Surgery
Surgery is the first modality for the treatment of malignant glioma [4]. However,
in contrast to tumors that have metastasized to the brain, where sharp tumor borders are
observed, borders of most glioma are ill-defined. Due to the high invasive and infiltration
property of glioblastoma, groups of tumor cells or single tumor cells can detach from the
primary tumor and travel a long distance to other sites of the brain. Thus it is not possible
to achieve complete tumor recession during surgery, which may contribute to the poor
prognosis of glioblastoma. Whether the extent of surgical resection statistically correlates
with overall survival is still a controversy in the literature. But decompressing the brain
by surgery temporally reduces the related clinical symptoms caused by the tumor, thus
improving the quality of life. Tumor samples taken during surgery can be sent for
histopathology review.
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In 2006, Stummer et al. reported that 6 month event-free survival of patients with
malignant brain tumors can be doubled using fluorescence-guided surgery [18]. They
conducted a randomized, controlled multicentre phase III trial giving treatment group
patients the non-fluorescent prodrug 5-aminolevulinic acid (ALA) by oral administration.
This prodrug was then metabolized to fluorescent protoporphyrin IX (PpIX). PpIX
accumulates high in tumor tissue and very low in normal tissue. Under blue light,
neurosurgeons can visualize the tumor as “red” in color, thus optimizing tumor resection.
Currently, ALA is not approved by the FDA for using during surgery.
In addition to classic surgery, neuroendoscopy provides a novel, minimally
invasive approach for the diagnosis and treatment of glioblastoma [19]. Utilizing a fiber
optic camera (endoscope), neuroendoscopy can be performed by a neurosurgeon to
visualize the tumor and perform biopsy, resection, and the concurrent management of
obstructive hydrocephalus associated with a tumor. The diameter of the neuroendoscope
is less than 1 cm, the skin incisions are less than 2 cm, and the opening of the skull is less
than 1 cm. This technique is very attractive, because it causes less damage to the brain
during the surgery. The visualization property of neuroendoscopy can help in getting
accurate glioma sampling for accurate pathological diagnosis. But some limitations of
this technique still need to be solved before it can get widespread popularity.
1.1.3.2. Radiation therapy
Radiation therapy is a mainstay treatment of malignant glioma in adults.
Published data that showed significant prolongation of survival for patients receiving
post-surgery radiotherapy (9 - 10 months) compared to surgery alone with supportive
care (4 - 5 months) [20-22]. The current routine regimen is 6 weeks of fractionated (60
Gy in 30 fractions) external-beam partial brain radiation starting at least 2 weeks after
tumor resection [20]. If the radiation source is focused precisely on the tumor, radiation
may cause more damage to tumor cells than it does to normal cells. The target volume for
radiation is often set as a 2 cm ring of brain tissue beyond the preoperative
contrast-enhancing rim of tumor determined by MRI or CT scan [20].
Radiation therapy for recurrent glioblastoma is more toxic and risky than for
newly diagnosed disease. Therefore, re-irradiation is limited to patients with focal disease
and good performance status, and both treatment volumes and dose are reduced [16].
Recent technical advances, such as modern treatment planning software and
commercial onboard imaging systems, have improved focusing of radiation by mapping
the tumors and setting up patients more accurately. Proton therapy is the most promising
frontier in radiation delivery [16].
1.1.3.3. Chemotherapy
Historically, chemotherapy plays a less prominent role in glioma treatment.
Currently, there are five FDA-approved antiglioma drugs: oral lomustine (CCNU),
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intravenous carmustine (BCNU), oral temozolomide (TMZ), biodegradable polymer
wafer impregnated with BCNU (Gliadel®), and monoclonal antibody bevacizumab [23].
Nitrosoureas CCNU and BCNU got approved for brain tumors in the 1970s. They
are DNA alkylating agents capable of crossing the blood-brain barrier (BBB) [23].
Adding them to radiotherapy provides a survival advantage of about 2 months. CCNU is
a component of the once popular PCV (procarbazine, CCNU, and vincristine)
combination therapy. BCNU has been the gold standard for evaluating new
chemotherapy for more than 20 years. However, substantial hematopoietic, pulmonary,
and renal toxicity have limited the usage of systemic nitrosoureas [21].
Gliadel® are 1.4 cm × 1 mm polifeprosan 20 wafers containing 7.7 mg/disc of
BCNU. Usually, up to 8 discs are implanted into the cavity after tumor mass resection.
BCNU can be released into brain parenchyma over days or weeks, while the polymer
matrix is degraded under the effect of interstitial water. The local BCNU concentrations
can be 1200-fold higher than the concentrations after intravenous administration. In the
meantime, peripheral toxicity can be largely reduced. Gliadel was first approved by the
FDA in 1996 for treatment of recurrent glioblastoma. Then in 2003, the FDA approved it
for initial treatment of all high-grade malignant gliomas since clinical trials showed that
median survival of the Gliadel group was more than 2 months longer than the placebo
group [21].
TMZ is an imidazotetrazine derivative of alkylating agent dacarbazine (DTIC). It
works as a prodrug: Under physiological pH, TMZ is hydrolyzed to the compound
monomethyl triazone imidazole carboxamide (MTIC). Unlike other approved antiglioma
drugs or the intravenous anti-melanoma agent dacarbazine, TMZ is almost 100%
bioavailable and can cross BBB after oral dosing [20, 21]. Its mechanism of action is the
methylation of DNA. TMZ got accelerated approval in 1999 for refractory anaplastic
astrocytoma and then regular approval in 2005 for newly diagnosed glioblastoma [23]. It
has become the current standard treatment for gliomas due to causing fewer side effects
(mainly hematopoietic and some moderate gastrointestinal toxicity) and offering
convenient oral dosing. The approved dosing regimen is 75 mg/m2 daily concomitantly
with radiotherapy, followed by 200 mg/m2 for 5 days every 4 weeks for a total of 6
months. The median survival benefit from adding TMZ to radiotherapy is 2.5 months
[21].
TMZ and nitrosoureas are both confronted by the drug resistance conferred by
DNA repair enzymes in glioma cells, such as apurinic/apyrimidinic endonuclease (APE),
poly-ADP-ribose-polymerase (PPAR), and especially the O6-methylguanine–DNA
methyltransferase (MGMT) [4, 20, 21, 24]. MGMT silencing by the promoter
methylation, which is found in less than half of glioblastoma patients, is associated with a
better response to TMZ. Depletion of MGMT by using more intense TMZ dose is also
believed to increase survival time. However, MGMT inhibitors have limited efficacy to
boost the effect of TMZ and nitrosoureas. In a rat glioma model, PPAR inhibitor
veliparib enhanced the efficacy of TMZ [25].
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In recent years, molecular targeted therapies for glioblastoma, which are supposed
to be more effective and selective, have been a hot topic. The underlying rationale for
these therapies is that some common genetic alterations occur within most glioblastomas,
which lead to dysregulation of cellular signaling pathways (e.g., Ras/Raf/ PI3K, p53, and
RB) and enable invasiveness, proliferation, evasion of apoptosis, avoidance of immune
surveillance, and angiogenesis. Many different types of targeted agents have been
investigated for malignant glioma treatment. They are EGFR inhibitors (gefitinib and
erlotinib), EGFR McAbs (cetuximab and nimotuzumab), VEGFR inhibitors (cediranib),
VEGF McAbs (bevacizumab and aflibercept), PDGFR inhibitors (imatinib), multiple
targeted RTK inhibitor (vandetanib ,sunitinib, and sorafenib), Akt inhibitors (perifosine),
PI3K inhibitors (BEZ235), Src/Abl inhibitors (dasatinib), PKC-β inhibitors (enzastaurin),
farnesyltransferase inhibitors (tipifarnib and ionafarnib), mTOR Inhibitors (sirolimus,
temsirolimus, and everolimus), proteasome inhibitors (bortezomib), HSP90 inhibitors
(AT13387), hepatocyte growth factor McAbs (AMG-102), integrin inhibitors
(cilengitide), as well as histone acetyltransferase and histone deacetylase (HDAC)
inhibitors (vorinostat and depsipeptide) [26, 27]. Challenges for molecular targeted
therapies include the molecular diversity and heterogeneity as well as redundant parallel
signaling pathways in glioblastomas. Most single-agent clinical trials of first generation
molecular targeted agents have been disappointing. Combination therapies may be
helpful in overcoming this problem. Another important finding is that the toxicities of
molecular targeted agents are higher than expected [28].
Despite of these frustrations, one molecular target agent, bevacizumab, made its
way to FDA approval for treatment of recurrent glioblastomas in 2009. Glioblastoma is
one of the most vascularized cancers. The level of angiogenesis mediator VEGF in
glioblastomas is correlated with malignancy and aggressiveness as well as recurrence and
poor survival. The accelerated approval for bevacizumab is based on high radiographic
response rates and low toxicity. It can also provide symptom relieve by decreasing
tumoral and peritumoral edema. The recommended dose is 10 mg/kg intravenously every
2 weeks. Besides direct inhibition of tumor angiogenesis, other mechanisms of action of
this drug include a direct antiglial effect on VEGF receptor-expressing tumor cells,
disruption of the microvascular niches for tumor stem cells, as well as improvement of
drug and oxygen delivery by vascular normalization [29-31].
Irinotecan, a topoisomerase I inhibitor currently approved for metastatic
colorectal cancer, can readily cross BBB. Irinotecan is synergistic with both
temozolomide and bevacizumab in combination therapy studies for glioblastomas. The
toxicities of these combinations are acceptable. The irinotecan and bevacizumab
combination may significantly improve survival in newly diagnosed glioblastoma cases
[32].
Other novel chemotherapies under development include dendritic cell vaccines
(DCVax), tumor-specific peptide vaccines (EGFRvIII peptides), immunotoxin (TP-38),
radiolabeled antibodies, and various gene therapies [27].
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1.1.3.4. Multimodal treatment
For newly diagnosed glioblastoma, a multimodal treatment, including tumor
resection, irradiation, and chemotherapy is recommended for adults whenever possible.
For recurrent glioblastoma, reoperation may relieve symptoms, but can only prolong
survival for 3 months, while re-irradiation is controversial [33]. Thus chemotherapy-only
regimens using TMZ or bevacizumab are often adopted. Guidelines for the management
of newly diagnosed glioblastoma [34] are summarized in Table 1-2.
1.2. Pharmacokinetics Considerations in Antiglioma Drug Discovery and
Development
1.2.1. Role of pharmacokinetics in drug discovery and development
Drug discovery and development is a high-risk and high-cost process. A recent
study shows that the total capitalized cost per approved new molecule have risen to
around 1.3 billion (2005 US dollars) [35]. A significant part of this figure is the cost of
failures, especially the attrition in clinical development. The clinical approval success
rate in the United States is only 19% for drug candidates that entered clinical trials
between 1993 and 2004 [36].
Since clinical development is the most expensive stage in the whole drug
discovery and development process, an important strategy has been to “fail early” the
compounds with poor “drugability” based on drug metabolism and pharmacokinetics
(DMPK) evaluation. In 1991, poor pharmacokinetic characters were the most frequent
cause (~ 40%) of attrition in clinical development [37]. By 2000, these type of issues are
responsible for less than 10% of attrition after the pharmaceutical industry addressed this
problem by improving the DMPK evaluation in the drug discovery stage [38].
1.2.2. A major challenge for antiglioma chemotherapy: the blood-brain barrier
For discovery and development of drugs that have a site of action in the brain, like
antiglioma drugs, biopharmaceutic evaluation is critical since these drugs need to
overcome an additional obstacle: the blood-brain barrier (BBB).
The brain is a well-perfused organ with the average human brain receiving 14%
of cardiac output. The brain capillaries have a total length of about 400 miles, and total
area of about 20 m2. The thickness of the endothelial cell is only 200 nm, less than 5% of
the thickness of most cells, and each brain cell is less than 25 µm away from the blood
flow [39]. However, more than 98% of small molecule drugs and almost all large
molecular drugs are kept from entering the brain by the BBB ─ a combination of a
proteinaceous layer (basal lamina) and three types of cells (brain capillary endothelial
cells (BCECs) monolayer, astrocytes, and pericytes) [40].
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Table 1-2． Guideline for the management of newly diagnosed glioblastoma
Therapeutic modalities
Neurosurgery

Level I recommendations
N/A

Level II recommendations
“Maximal safe resection” is
recommended for newly
diagnosed supratentorial
malignant glioma in adults.

Radiation therapy

Radiation therapy is
recommended for the treatment
of newly diagnosed malignant
glioma in adults. Treatment
schemes should include dosage
of up to 60 Gy given in 2 Gy
daily fractions that includes the
enhancing area.

Radiation therapy planning
includes a 1 to 2 cm margin
around the radiographically
defined T1 contrastenhancing tumor volume or
the T2 weighted
abnormality on MRI.

Chemotherapy

Concurrent and post-irradiation
temozolomide is recommended
in patients 18 to 70 years of age
with adequate systemic health.

BCNU-impregnated
biodegradable polymers are
recommended in patients for
whom craniotomy is
indicated.

Level III recommendations
Biopsy, partial resection or gross total
resection is recommended to be
considered in the initial management
of malignant glioma.

1) TMZ + radiation for patients (> 65
years old) with newly diagnosed
glioblastoma with KPS > 50; 2) For
patients are ≥ 70 years old, with
newly diagnosed glioblastoma, TMZ
alone is a well-tolerated alternative to
radiation therapy; 3) Radiation
therapy, followed by one of the
nitrosoureas, is recommended for
those patients not eligible for TMZ.

Source: Adapted with permission. Olson, JJ, et al., Management of newly diagnosed glioblastoma: guidelines development, value and
application. J Neurooncol, 2009. 93(1): p. 1-23.
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Unlike endothelial cells, which are only connected by adhesion junctions to form
the porous peripheral capillaries, BCECs are connected by both adhesion junctions and
tight junctions. Tight junctions are protein complexes that consist of the intercellular cleft
proteins occludin and claudins as well as junctional adhesion molecules (JAMs).
Occludin and claudins are linked to cytoplasmic scaffolding proteins zonula-occludens
(ZO)-1, ZO-2 and ZO-3, which are in turn linked to the actin/myosin cytoskeletal system
via cingulin. Paracellular transportation is effectively prevented by tight junctions [40]. In
addition, alternate transport pathways, e.g., fenestrations, transendothelial channels and
pinocytotic vesicles are also lacking in BCECs [41].
On the other hand, BCECs have a large number of mitochondria and drug
metabolic enzymes that make them metabolically competent. The ABC (ATP-binding
cassette) family of efflux transporters, e.g., P-glycoprotein (P-gp), breast cancer
resistance protein (BCRP), and multidrug resistance protein-1,2,4,5 (MRP-1,2,4,5) are
expressed on the luminal membrane of BCECs as an additional layer of protection from
xenobiotics [40-42].
The outside of the BCEC is partially covered by discontinuously distributed
pericytes. Also, the basal lamina covers both pericytes and BCECs as an extracellular
matrix. The outermost layer of the BBB is formed by the astrocyte foot processes
surrounding the basal lamina, pericytes, and BCECs. These astrocytes and pericytes help
induce and maintain the properties of BBB [40].
Given all these limiting factors, there are still some ways that molecules can cross
the BBB and get into the brain [40, 43, 44]:







Hydrophilic polar small molecular nutrients, e.g., glucose, amino acids,
nucleotides, nucleosides, monocarboxylates, organic cations, and organic anions,
can enter the brain through carrier-mediated transport (CMT) i.e., via solute
carriers (SLCs), at the luminal (blood) and basolateral (brain) side of BCECs.
Certain proteins and peptides, e.g., transferrin, melanotransferrin, lipoproteins,
insulin, leptin, tumour necrosis factor α (TNF-α), epidermal growth factor (EGF),
leukaemia inhibitory factor (LIF), and diphtheria toxin can be transported through
receptor-mediated transcytosis (RMT).
Some protein with excess positive charge, e.g., histone, protamine, avidin, and
cationised albumin can be transported through adsorptive-mediated transcytosis
(AMT).
Oxygen and lipophilic non-polar small molecules may passively diffuse through
the cell membranes and enter the brain. However, many small molecular drugs
that enter the BCECs will be kicked back to the blood by the efflux transporters at
the luminal side and/or exposed to drug metabolism inside the BCECs.

The blood-cerebrospinal fluid (CSF) barrier (BCSFB), which separates blood
from the CSF in the choroid plexus, has a structure different from the BBB. The
fenestrated choroid plexus capillary endothelium allows diffusion of small molecules,
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while the barrier function is carried out by choroid epithelial cells that form tight
junctions [40].
Malignant gliomas can secrete excess vascular endothelial growth factor (VEGF)
and induce angiogenesis. In the tumor neovasculature, the tight junction proteins claudins
and occludin as well as the cytoplasmic scaffolding protein ZO-1 are often either
downregulated or lost. The number of pinocytic vesicles is increased in tumor endothelial
cells [45]. In addition, abnormalities have been found in pericyte and basal lamina [45].
All these changes lead to a partially functional blood-brain barrier, or so-called
blood-brain tumor barrier (BBTB) [46]. The peritumoral edema, endothelial hyperplasia,
and gadolinium-contrast enhancing lesions in MRI are caused by this leaky barrier [45].
It has been posited that the BBB should not hinder glioma chemotherapy at all,
since drugs should be able to pass at the leaky BBTB area [47]. However, the mainstream
opinion is that even the BBTB is still a real barrier to transportation of antiglioma drugs.
Although weakened, the tight junction is still present in BBTB, and the fenestrations are
still rare (~ 2%) [45]. High interstitial pressure in the tumor caused by the leaky
vasculature can slow drug extravasation, which can at least partially counterbalance the
leaking-caused penetration increase [46]. Expression of some drug efflux trasporters,
such as MRP1, is upregulated in the BBTB [46]. The most important point is that the
leaky BBTB is only formed in the center of well-established tumors as a result of tumor
neovascularization. The proliferating edge of the tumor and wide-spread tumor cells at
the infiltrated area are still fed by established microvessels, thus being protected by
normal BBB [46, 48-50].
1.2.3. Strategies for enhancing brain penetration of antiglioma drugs
Various strategies have been developed to overcome the limitations of the
BBB/BBTB on antiglioma drugs.
1.2.3.1. Circumventing BBB by local administration
Challenges posed by BBB can be overcome directly by administering drugs to the
brain interstitium. There are three types of approaches for local administration of
antiglioma drugs: intraventricular/intracavitary injection, impregnated polymer
implantation, and convention enhanced delivery (CED).
1.2.3.1.1. Intracerebroventricular or intracavitary injection. A frequently used
intracerebroventricular or intracavitary delivery device is the Ommaya reservoir, which is
named after the inventor, Ayub Khan Ommaya. It consists of a mushroom-shaped
self-sealing silicone dome placed under a flap of scalp and a connected catheter that goes
to the ventricle or cavity through a small opening on the skull. Drug is injected into the
dome first. Then the dome is flushed and gently pressed to force the drug through the
catheter and into the brain. In this way, intermittent bolus injections of anticancer drugs
can enter directly into the CSF, tumor cyst, or resection cavity. Prolonged
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intracerebroventricular infusion can be carried out by other pump and catheter systems
[49, 51, 52].
This type of drug delivery approach is limited by the slow rate of drug diffusion
to brain parenchyma. With the intracerebroventricular route, the situation is even worse.
Although CSF and interstitial fluid (ISF) can communicate freely, the CSF bulk flow
passes through the ventricle and is absorbed into blood at the superior sagittal sinus in a
rate much faster than the rate of drug diffusion. As a result, a remarkable portion of the
intracerebroventricular-administrated drug exits to peripheral blood flow before entering
the brain parenchyma [39]. Other disadvantages of this type of approach include infection
and catheter obstruction [52].
1.2.3.1.2. Impregnated polymer implantation. Another type of local delivery
approach is implantation of various drug-impregnated polymers into the tumor resection
cavity. These polymer implants are different from each other in impregnated drugs, ratecontrolling mechanisms, degree of biodegradability, and also shapes and sizes [46].
As mentioned in 1.1.3.3., Gliadel®, a poly(carboxypropane)-sebacic acid (PCPPSA, belonging to polyanhydrides)-based biodegradable polymer wafer containing
carmustine (BCNU), has been approved for gliobalstoma treatment. Clinical trials for
paclitaxel- and cisplatin-containing polymer implants have been conducted. In addition,
polymers impregnated with other drugs, such as adriamycin, 5-fluorouracil, mitomycin,
nimustin hydrochloride, and mitoxantrone have been studied in preclinical settings [46,
52, 53]. Besides wafers, the polymer implant can also take the form of drug-loaded
microspheres [49].
Release of drug from the implant is driven by hydrolytic degradation of polymer,
while the distribution is driven by a concentration gradient, i.e., the principle of diffusion.
A very high drug concentration can be achieved at the tumor resection site where the
polymer is planted [49, 52, 53], and that concentration can be maintained for weeks [48].
Although BCNU can pass the blood-brain barrier after systemic administration due to its
high lipophilicity, when it is given as Gliadel, the dose-limiting systemic toxicities can be
minimized [53].
As a result of the diffusion process, the concentration of the drug decreases
exponentially with distance in brain parenchyma surrounding the resection cavity [43].
The interstitial pressure adjacent to the cavity can also hinder the drug diffusion [53].
Thus, the drug concentration just millimeters away from the resection cavity is often too
low to treat the glioma cells effectively [48, 50].
Other limitations of the impregnated polymer approach include local
neurotoxicity, poor wound healing, infections, cerebral edemas, and obstructive
hydrocephalus [49, 53].
1.2.3.1.3. Convention-enhanced delivery. Convention-enhanced delivery (CED)
is a novel approach proposed by Bobo et al. It infuses antiglioma drugs via a catheter (s)
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within or around the tumor by hydrostatic pressure. Unlike the aforementioned
intraventricular/intracavitary injection and impregnated polymer implantation
approaches, the drug movement from the site of administration is driven by not only the
principle of diffusion, i.e., the concentration gradient, but also the bulk flow of the
infusate, i.e., the pressure gradient. Thus, a quicker and wider distribution can be
achieved through CED. Targeted delivery of antiglioma drugs is achieved by selection of
the catheter location. Using CED can limit systemic toxicity as well as widespread
neurotoxicity [46, 50, 52].
Key parameters that need to be considered in CED are: infusion rate, catheter
size, infusion volume, interstitial fluid pressure, particle characteristics, and tumor tissue
structure. When carefully implemented, CED only causes inflammation within 50µm of
the catheter surface and does not cause cerebral edema or measurable increases in
intracranial pressure. CED has been used for delivery of viral vectors, paclitaxel,
topotecan, transferrin/diphtheria toxin, IL-4 and IL-13 targeted toxins, IL-4, TP-38, and
TGF-β [52].
In the other hand, CED is still plagued by a limited distribution area, like other
local delivery routes. As a result, it is best used against small solid tumors. In order to kill
infiltrative tumor cells, multiple catheters and multiple day infusions may be necessary.
This makes CED a rather invasive approach. Some indigenous drawbacks of CED, such
as catheter-induced tissue damage, reflux of solute adjacent to the catheter, “intrinsic”
backflow of solute, and air bubbles, can lead to unpredictable and undesirable drug
distribution [46, 48, 50, 52].
1.2.3.2. BBB disruption
Another class of strategy to overcome the limitation of BBB is to disrupt it
physically or biochemically when administrating an antiglioma drug systemically.
1.2.3.2.1. Osmotic disruption. Intracarotid infusion of hyperosmotic solution,
e.g., mannitol solution, can draw intracellular water to the vascular lumen from BCECs.
This leads to BCECs shrinkage and subsequent opening of the tight junctions for hours.
Thus the paracellular transportation is permitted at that time. Chemotherapy drugs are
often dosed through intra-arterial route when this approach is used [49, 52, 53].
Animal studies show that osmotic BBB disruption can increase drug
concentrations in the brain parenchyma by up to 90-fold [52]. Enhanced drug delivery to
the brain by this method has also been shown in humans [50].
However, this method causes greater disruption of the normal BBB than to the
BBTB, which may result passage of toxic proteins and too much chemotherapy drug to
normal brain tissue. Other adverse effects include physiological stress and increase in
intracranial pressure [48, 50].
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1.2.3.2.2. MRI-guided ultrasound disruption. This approach can generate a focal
BBB disruption, other than the global disruption caused by osmotic disruption [43, 52].
Since the cranium can attenuate ultrasound, a bone window is usually a prerequisite.
Then the process begins with intravenous injection of preformed bubbles. The pulsed
ultrasound guided by MRI is applied to the desired area to localize cavitation-generated
mechanical stresses to brain capillary walls. The resulting BBB disruption is reversible
and can completely recover in 24 hr. Increased brain penetration of herceptin and
liposomal doxorubicin has been shown after using this approach in mice and rat,
respectively.
1.2.3.2.3. Biochemical disruption. Biochemical BBB disruption involves using
vasomodulators, such as leukotrienes, histamine, bradykinin, nitric oxide donors, soluble
guanylate cyclase activator, potassium, calcium, and ATP channel agonists. Unlike the
osmotic disruption, this method primarily affects BBTB [48, 52]. Thus chemotherapy
after biochemical BBB disruption is more selective on tumor mass with
neovascularization, and is less toxic to normal brain tissue. However, as discussed in
1.2.2, glioma cells at the edge of the tumor or infiltrated areas is still protected by normal
BBB and thus are not exposed to drug concentration that is high enough to be effective.
Calcium can regulate tight junction assembly and the effectiveness of the tight
junctions as a barrier [40]. Bradykinin analogue RMP-7 can indirectly activate
calcium-mediated tight junction opening by activating B2 bradykinin receptors [43]. In
animal studies, RMP-7 increased brain penetration of the hydrophilic compounds
carboplatin and dextran, with greater impact in regions of BBTB [52]. However, it failed
in clinical trials in combination with carboplatin [43].RMP-7 had no obvious impact on
brain penetration of the lipophilic drug BCNU.
Common shortcomings of all of these three BBB disruption approaches include
[43] requirement of anesthesia and hospitalization, potential damage of neurons caused
by entering of some blood components, and potential of facilitating tumor dissemination.
1.2.3.3. Inhibition of drug efflux transporters
Drug transporters in BBB form an additional functional barrier. Thus inhibition of
these transporters will also benefit the drug brain penetration. P-gp is the most important
drug efflux transporter at the BBB. Brain penetration of paclitaxel, docetaxel, and
imatinib has been improved by co-administration of P-gp inhibitors in animal studies.
Classical P-gp inhibitors, e.g., verapamil and cyclosporine A have low affinities and high
toxicity. Using cyclosporine A analogue valspodar can overcome these problems. Like
verapamil and cyclosporine A, valspodar is also a CYP3A inhibitor. This may not be a
desirable characteristic, because CYP3A does not express at a high level in the human
BBB [54] but plays a key role in the peripheral drug metabolisms of many drugs. The
newest generation of P-gp inhibitors without CYP3A-inhibiting activity, such as elacridar
(also a BCRP inhibitor), zosuquidar, and tariquidar, are better tools to increase brain
penetration of antiglioma drugs. BCRP inbibitors such as pantoprazole may also useful
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for this purpose [46]. Some nanocarriers , such as Pluronic block copolymers micelle can
also inhibit drug efflux transporters in the BBB [55].
1.2.3.4. Taking advantage of BBB carriers and transporters
Carrier and transporter systems in the BBB also have been utilized to develop
noninvasive strategies for brain penetration enhancement. These strategies can be either
using nano-sized drug carriers conjugated to ligands of those transporter systems or
making the drug molecules mimic or directly coupled to those ligands.
OX26 is a murine monoclonal antibody (McAb) against rat transferrin receptor
(TfR). As a peptidomimetic McAb, OX26 binds TfR through a domain not in the
transferrin (Tf)-binding site and thus does not interfere with endogenous Tf binding.
OX26-conjugated liposomes can significantly increase the brain penetration of
daunomycin through TfR-mediated transcytosis [49].
Some evidence suggests existence of a sodium-dependent, reduced glutathione
(GSH) transporter in BBB [56]. Recently, GSH-conjugated PEGylated liposomes of
doxorubicin showed promising results in proof-of-concept studies.
Polysorbate-80 (Tween 80)-coated nanoparticles also can increase drug brain
uptake. The mechanism supported by most abundant evidence is as follows: The
polysorbate-80-coated nanoparticles adsorb apolipoprotein (Apo) E or B from blood to
their surface─in other words, indirectly conjugated to apolipoproteins─and then cross the
BBB through low density lipoprotein (LDL) receptor-mediated transcytosis.
Polysorbate-80 coated-poly (butylcyanoacrylate) (PBCA) nanoparticles can increase the
brain concentration of doxorubicin after systemic administration for more than 50 times
[57, 58].
DL-2-amino-7-bis (2-chloroethyl)amino]-l,2,3,4-tetrahydro-2-naphthoic acid
(DL-2-NAM-7), a melphalan analog with higher affinity to large amino acid (LAT)
transporter, shows 20 times higher brain uptake than melphalan [59].
Angiopep-2, a 19 amino acid peptide, can cross the BBB though lipoprotein
receptor-related protein-1 (LRP1)-mediated transcytosis. Paclitaxel conjugated to
Angiopep-2 (ANG1005) distributes into the brain at a level 4 to 5 times higher than
paclitaxel alone [48].
1.2.3.5. Passive diffusion enhancement by drug structure modification
The physio-chemical parameters of anticancer drugs can be tuned to optimize
passive diffusion across the BBB. For example, making a lipophilic analog or prodrug of
a highly hydrophilic drug may help its diffusion. More details on the optimal drug
physio-chemical properties for brain penetration are discussed in the next section.
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1.2.4. Physiochemical characteristics of successful CNS drugs
Prediction of brain penetration of new chemical entities (NCEs) from their
physiochemical properties is a hot but controversial area [60]. Following are some simple
physiochemical rules for successful CNS drugs summarized by Pajouhesh et al. [61]:







Molecular weight < 450
cLogP < 5
H-bond donors < 3
H-bond acceptors < 7
Rotatable bonds < 8
Polar surface area (PSA) < 60–70 Å2

These rules can serve as a rough guideline for discovery of novel antiglioma drug
intended for systemic administration or structure modification of current drugs.
Comparison between these rules and Linpinski’s “rule of five”, i.e.,






Molecular weight ≤ 500
LogP ≤ 5
H-bond donors ≤ 5
H-bond acceptors ≤ 10
Rotatable bonds ≤ 10

shows CNS drugs have lower molecular weights, less flexibility, and fewer hydrogen
bond donors and acceptors [61].
The limit on LogP may be explained as follows: While higher lipid solubility
helps passing the phospholipids bilayer, it can also lower the concentration of the free
drug available for diffusion at BBB [62] because of increased peripheral tissue and
plasma protein binding. In addition, drugs already in the BCECs need to partition into the
aqueous environment of brain interstitial fluid before reaching their target behind the
BBB [41]. Also, high non-specific binding to brain tissue will hinder drugs with very
high lipophilicity from exerting their effect. Some earlier reports even suggested a value
around 2 as the optimal LogP for CNS drugs [61].
Compared to the absorption process in the gastrointestinal tract, BBB crossing is
more dependent on transcellular diffusion. The movement of lipid-soluble molecules
through the cell membrane is hypothesized to be through transient pores created by
kinking of the mobile unsaturated fatty acyl side chains in the phospholipid bilayer. Thus
the size and shape of those holes determine the size and shape of the molecules that can
pass [39]. This may explain why CNS drugs are smaller than general oral drugs and have
more compact and less flexible structures.
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In addition, certain physiochemical features may play a role in substrate
specificity of efflux transporters and drug metabolism enzymes, thus affecting drug brain
penetration.
1.2.5. Overview of DMPK of last generation of EDL compounds
1-[(4-phenylphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol (Figure 1-2),
i.e. , EDL-155, also known as EDL-1, is a tetrahydroisoquinoline derivative with in vivo
antiglioma activity selected from about 500 compounds synthesized by Dr. Duane
Miller’s laboratory at The University of Tennessee Health Science Center (UTHSC,
Memphis, TN) [63, 64]. It was the subject of a detailed DMPK evaluation in Pengfei
Song’s dissertation [63].
After 10 mg/kg intravenous injection to rats, EDL-155 demonstrated
extraordinarily rapid clearance (342.5 mL/min/kg), which is around 6 times the rat liver
blood flow. The volume of distribution was estimated at 13.0 L/kg. Elimination of
EDL-155 can be described by a one-compartment model [65]. EDL-155 is extensively
bound to plasma proteins, with the percentage bound being larger than 93 at
concentrations of 150, 650, and 2,500 ng/mL [65]. The most abundant EDL-155
metabolite is formed by C-ring hydroxylation, which may be catalyzed by a cytochrome
P450 enzyme. The next abundant metabolite is formed by A-ring mono-methylation,
which may be catalyzed by catechol O-methyltransferase (COMT) in blood and tissue
[65]. EDL-155 was predicted by Song to be a P-gp substrate using an in silico
classification structure-activity relationship (C-SAR) model based on physicochemical
properties, which was verified subsequently using Calcein-AM assay [63].
Some potential reasons for the high clearance value were proposed: 1)
accumulation in blood cells, fat, and other organs, 2) degradation/metabolism in the
blood, 3) first pass effect in the lung, and 4) exsorption into the gut by uptake
transporters. However, these possibilities were not examined by experiments in Song’s
study [63].
The brain penetration of EDL-155 was evaluated in vivo by CSF sampling after
20 mg/kg intravenous injection in rats. The dose-normalized ratio of AUCCSF/AUCPlasma
was calculated to be 1.4% [65]. As an attempt to overcome the poor brain penetration
problem, 9.25 mg/mL EDL-155 solution was delivered as 4 µL/min × 100 min CED
infusion in caudate nucleus. Although EDL-155 can be detected in the contralateral
frontal lobe, ipsilateral lobe, occipital lobe, and the cerebellum, the concentration in these
areas is less than 0.2% of the injection site concentration [63].
EC50 of EDL-155 is 1.5 mM for rat C6 glioma cells [64]. Despite its limited
brain penetrability, after 7 days of 20 mg/kg intraperitoneal injections, it still can cause
29.4% growth inhibition of the intracranial implanted C6 glioma in rats [66]. This
suggests that analogs with increased metabolic stability and brain penetrability may
provide a therapeutic option for glioma.
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Figure 1-2.

Structure and selected physiochemical properties of EDL-155

Exact mass and cLogP are calculated by ChemDraw Ultra 12.0 (CambridgeSoft
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18

Study of analogs of EDL-155 showed that replacing the A-ring catechol hydroxyl
groups with dimethoxy may sometimes increase metabolic stability and decrease
clearance. However, their CSF concentration is lower than that of some EDL-155 analogs
that keep A-ring catechol hydroxyl groups. A closer inspection showed that
AUCCSF/AUCPlasma decreased with the increase of LogP [63].
1.3. Background for Mechanism of Action Study
1.3.1. Drug discovery with unknown target
Phenotypic (physiological or cellular) screening is a classical drug discovery
method [67-69]. Since 1990s, this low-through-put approach has been largely replaced by
the molecular target-based screening, which is powered by advances in molecular
biology, genomics, and combinatorial chemistry. However, after the initial euphoria, the
new gene-to-drug paradigm turned out to be not as productive as expected, and was
criticized for “targephilia” and overtly reductionism [70]. Therefore, the old route,
phenotypic screening, has seen a renaissance, as supporters argue that it can test the
compounds against the actual complex biological system in the very beginning [71]. In
2002, Merck received approval of ezetimibe, a cholesterol-lowering agent discovered
through phenotypic screening. Eli Lilly also announced a Phenotypic Drug Discovery
(PD2) Initiative in 2009.
The phenotypic screening can bypass the prior target identification and validation,
and thus allows discovery of drug candidates with unknown targets. However, at the
present time, a drug candidate discovered via this route must undergo a mechanism of
action study or even a retrospective target identification [68]. In the case of ezetimibe, if
the decade long mechanism-finding effort had been unsuccessful, it would not likely gain
approval. A successful mechanism study can also facilitate further optimization of
structure, identification of potential toxicities or side effects, and selection of possible
responders for clinical trials [67, 68, 71].
1.3.2. Discovery of EDL compounds
The lead compound of EDL series compounds was found in an anti-hepatitis C
drug discovery project at The University of Tennessee Health Science Center. It was
designed as a blocker of CD81 (TAPA-1, target of antiproliferative antibody-1), a cell
membrane protein that is important for Hepatitis C virus (HCV) attachment and cell
entry. CD81 signals for antiproliferation when bound by antibodies. Rat astrocytes are
CD81 enriched, while C6 rat glioma cells are CD81-deficient. Thus, CD81 blocker that
mimics the effect of CD81 antibodies should have an antiproliferative effect on rat
astrocytes but not on C6 cells. Surprisingly, that lead compound inhibits the growth of C6
glioma cells instead of rat astrocytes [72, 73]. After that discovery, structure
modifications were made to improve the antiglioma activity and give birth to the EDL
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series of 1, 2, 3, 4-tetrahydroisoquinoline derivatives [64]. The cell proliferation assays of
rat astrocytes, C6 cells, and human glioblastoma cell lines were used to screen these
compounds. Therefore, EDL series of antiglioma compounds were discovered by
serendipity and screened by phenotypic screening. Their mechanism of action was
unknown before the start of this dissertation research.
1.3.3. Cell death pathways induced by chemotherapy
All anticancer drugs induce cancer cells’ death, but those cells die through
different pathways. The five major modes of cell death induced by chemotherapy are
apoptosis, autophagic cell death, necrosis, mitotic catastrophe, and senescence [74].
1.3.3.1. Apoptosis
Apoptosis also called type I programmed cell death, is a well-known means of
cancer cell death after chemotherapy. The morphologic characters of apoptosis include
cell shrinkage, nuclear condensation and fragmentation, exposing of phosphatidylserine
on the cell surface, membrane blebbing, and eventually fragmentation into
membrane -bound apoptotic bodies. The two most well-known apoptosis signaling
pathways are the intrinsic pathway and extrinsic pathway [74-78].
Many traditional chemotherapeutic drugs can trigger the intrinsic pathway by
transcriptional upregulation and activation of BH3-only pro-apoptotic members of Bcl-2
family proteins such as Bad, Bim, Bmf, Noxa, and Puma. These proteins can antagonize
the effect of BH1-2-3-4 anti-apoptotic members of the BCL2 family proteins, such as
Bcl-2, Bcl-xl, and Mcl-1. The changed balance between BH3 only and BH1-2-3-4
proteins induces homooligomerization and mitochondrial outer membrane insertion of
the BH1-2-3 pro-apoptotic members of the Bcl-2 family proteins, like Bax and Bak, then
lead to mitochondrial outer membrane permeabilization (MOMP) through a MPT
(mitochondrial permeability transition)-dependent or a MPT-independent mechanism.
MOMP is a critical event in the intrinsic pathway; it demarcates the boundary
between death and survival. Once triggered, it irreversibly leads to cell death through
three mechanisms: 1) release of proteins that help caspase activation, such as cytochrome
C, Smac/DIABLO, and Omi/HtrA2; 2) release of pro-apoptotic proteins unrelated to
caspase activation, such as AIF (apoptosis-inducing factor) and Endo G (endonuclease
G); and 3) loss of mitochondrial functions essential for cell survival.
Cytochrome C released in MOMP binds Apaf-1, resulting in the formation of a
complex called apoptosome in the presence of ATP/dATP. The apoptosome can recruit
procaspase-9, cause procaspase-9 oligerization and auto-cleavage, which generates the
caspase 9. The caspase-9 and the apoptosome then form an active holoenzyme to activate
downstream executioner caspases -3, -6 and -7 through an internal cleavage to separate
the large and small subunits. The executioner caspase activities are essential for the
apoptotic phenotype. The bona fide substrates of executioner caspases include PARP,
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DFF45/ICAD, Rb, and ROCK I. As a positive feedback mechanism, the executioner
caspases also activate caspase-9.
IAPs (inhibitor of apoptosis proteins), such as XIAPs (X-linked inhibitor of
apoptosis proteins), inhibit caspase activity by directly binding to the active enzymes.
Smac/DIABLO and Omi/HtrA2 can enhance caspase activation as competitive inhibitors
of IAPs.
.
The so-called caspase-independent apoptosis is mediated by aforementioned AIF
and Endo G. They can translocate to the nucleus, induce peripheral chromatin
condensation and DNA fragmentation without the involvement of caspases.
Sometimes chemotherapeutic drugs can also activate the extrinsic apoptosis
pathway by upregulating the plasma membrane death receptors Fas, TNFR1, or DR4/5
through the involvement of p53. Binding of homotrimeric death ligands FasL, TNF-α, or
TRAIL to corresponding death receptors induces oligomerization of the death receptors.
The resultant ligand-receptor complex then further forms a DISC (death-inducing
signaling complex) by recruiting adapter proteins, such as FADD (Fas-Associated protein
with Death Domain) and TRADD (TNF-R1-Associated Death Domain). Three molecules
of procaspase-8/10 can join the DISC by binding to FADD, and then are activated by
auto-cleavage. In some cases (type I cells), the activation of executioner caspases -3, -6,
and -7 by caspase-8 and -10 is sufficient for apoptosis. In other cases (type II cells), the
caspase-8 also activate Bid, a pro-apoptosis member of the Bcl-2 family, thus activating
the intrinsic pathway.
A newer class of chemotherapy drugs, i.e., apoptosis-inducing molecular targeted
drugs, kills cancer cells by modulating the activity of particular molecules involved in
apoptosis, which are often dysregulated or even mutated in cancer cells [74-76].
Examples of these drugs include TRAIL ligand, TRAIL antibody, BH3 mimic
(gossypol), Bcl-2 antisense oligonucleotide, and proteasome inhibitor (bortezomib).
In addition to the aforementioned intrinsic, extrinsic, and caspase-independent
pathway, an ER (endoplasmic reticulum) stress-induced apoptosis pathway has been
reported recently [77-84]. Human caspase-4 and mice caspase-12 [85] are the initiator
caspases in this route [86]. They can directly activate caspase-3 [85, 87] and thus trigger
the downstream apoptosis events. Celecoxib, bortezomib and tunicamycin are examples
of drugs that induce apoptosis through this pathway [79].
1.3.3.2. Autophagic cell death
“Autopahgy” means self-eating. Briefly, in this process, a double membrane
vesicle forms in the cytosol that encapsulates whole organelles and bulk cytoplasm.
These so-called autophagosome structures then fuse with the lysosomes where the
contents are degraded and recycled [74-76, 88-90].
Autophagy can be triggered by various stimuli, including chemotherapy,
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radiation, nutrient deprivation, growth-factor withdrawal, bacterial infection, aggregated
and misfolded proteins (ER stress), and damaged organelles [74-76, 88-90]. In many
case, autophagy can be a pro-survival mechanism. It can produce amino acids during
nutrient starvation and eliminate unwanted and damaged organelles and molecules, thus
increasing the chance of a cell to survive stresses. But when this process becomes too
extensive, it leads to autophagic cell death, or type II programmed cell death [74-76,
88-90] .
The molecular events leading to autophagy are briefly summarized as follows
[74-76, 88-90]: Autophagy begins from cup-like double-layered membrane structures, the
isolation membranes. This autophagy induction/membrane nucleation process is
regulated by type I PI3K (phosphoinositide 3-kinase), type III PI3K, and mTOR
(mammalian target of rapamycin). Type I PI3K is active in a nutrient-rich environment
and can activate the mTOR through the serine/threonine protein kinases PDK1
(phosphoinositide-dependent kinase-1) and Akt (PKB). mTOR is a serine/threonine
kinase that inhibits autophagy through controlling transcription, translation, and
modification of autophagy-related (Atg) proteins. Thus inhibition of the type I
PI3K-mTOR pathway can induce autophagy. mTOR activity can also be affected by
many other mechanisms, and thus can coordinate signaling pathways that are initiated by
many nutritional and mitogenic factors. Autophagy can also be induced by lowering
inositol trisphosphate (IP3) level, an mTOR-independent way. Vps34, a type III PI3K
that includes berclin-1 (Atg6) in its complex, promotes the nucleation of autophagic
vesicles.
Autophagosomes are formed after elongation and closure of the isolation
membranes, which engulf the cytoplasmic materials (cytosol and/or organelles) [74-76,
88-90]. Two ubiquitin-like conjugation systems are part of this process. One system
involves the covalent conjugation of Atg12 to Atg5, with the help of the E1
(ubiquitin-activating enzyme) -like enzyme Atg7 and the E2 (ubiquitin carrier) -like
enzyme Atg10. Atg16L-binding to the Atg12-Atg5 complex is necessary for the
elongation of the isolation membrane and formation of the autophagosomal membrane.
This complex finally dissociates from the mature autophagosome. The second system
involves the conjugation of phosphatidylethanolamine (PE) to microtubule-associated
protein 1-light chain 3 (LC3)/Atg8 by the sequential action of the protease Atg4, the
E1-like enzyme Atg7, and the E2-like enzyme Atg3. Lipid conjugation causes conversion
of the soluble form of LC3 (named LC3-I) to the autophagic vesicle-associated form
(LC3-II).The targeting of LC3-PE to the isolation membrane or autophagosomal
membrane relies on the Atg12-Atg5 complex, but it will keep binding to the membrane
after Atg12-Atg5 leaves.
As the last step, the autophagosomes fuse with lysosomes [74-76, 88-90]. Before
this fusion, the autopahgosomes can fuse with endosomal vesicles first (amphisome). The
autophagosome outer membrane fuses with the lysosome (or endosome) membrane while
the inner sac (autophagic body) enters the lysosome, where its membrane as well as the
luminal content is degraded by lysosomal enzymes that act optimally within this acidic
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compartment. The formed single membrane-surrounded vesicle is called an
autophagolysosome or autolysosome.
The current first-line antiglioma drug, DNA-alkylating agent TMZ can induce
both autophagic cell death and apoptosis. Other drugs or drug candidates that can induce
autophagy in cancer cells include mTOR inhibitors everolimus and deforolimus, arsenic
trioxide, ceramide, endostatin, the histone deacetylase (HDAC) inhibitors butyrate and
vorinostat, neodymium oxide, saponins, curcumin, and resveratrol [74-76, 88-90].
1.3.3.3. Necrosis
Necrosis can be defined morphologically as cell and organelle swelling, or rupture
of surface membranes with spillage of intracellular contents [74, 75, 91]. Necrosis was
thought to be an uncontrolled process. But recently, more and more evidence shows that
necrosis can be a regulated event [74, 75, 91]. Some researchers called the regulated form
of necrosis type III programmed cell death. Inducers of necrosis include DNA damage,
inhibition of cellular energy production (ATP depletion), imbalance of intracellular
calcium flux, viral infection, excess generation of reactive oxygen species (ROS), and
activation of nonapoptotic proteases (e.g., calpain and cathepsin).
Necrosis can also be induced by chemotherapy [74, 75, 91]. DNA-alkylating
agents can activate PARP, while the hyperactivation of PARP depletes cytosolic
nicotinamide adenine dinucleotide (NAD) and induces necrosis. Photodynamic treatment,
β-lapachone, apoptolidin, and honokiol can also induce necrosis in cancer cells. Necrosis
inducing is not likely to be a promising approach to treat gliomas. In fact,
pseudopalisading necrosis is a hallmark of glioblastoma.
1.3.3.4. Mitotic catastrophe
Mitotic catastrophe refers to death that occurs during mitosis, resulting from a
combination of deficient cell-cycle checkpoints and cellular damage [75, 92, 93]. The
aforementioned cell-cycle checkpoints can be DNA structure checkpoints or the spindle
assembly checkpoint. Since cancer cells often have deficient cell cycle checkpoints, when
compared to normal cells, cancer cells are more susceptible to the induction of mitotic
catastrophe by chemotherapy drugs acting as DNA damaging agents or microtubule
poisons.
Some researchers believe that mitotic catastrophe is not an independent mode of
cell death [75, 92, 93]. They propose an alternative definition: Mitotic catastrophe is a
process characterized by the formation of multinucleated cells resulting from aberrant
mitosis, and is a “prestage” of apoptosis or necrosis.
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1.3.3.5. Senescence
Senescence is a state of permanent cell-cycle arrest [92, 94]. Senescent cancer
cells although alive, can be cleared by immune cells, resulting in cancer regression.
Therefore, senescence is also included in the cell death pathways.
Cellular stresses can activate tumor suppressors, e.g., p53, INK4A and ARF, and
trigger senescence [92, 94]. Senescent cells can secrete both tumor-suppressing factors
that reinforce the senescent phenotype and tumor-promoting factors that stimulate
malignant phenotypes in nearby cells. In pre-malignant tumors, most cells are senescent.
In malignant tumors, their ability to undergo senescence is impaired, but they can still be
forced into senescence by chemotherapy [92, 94]. In vitro studies show that classic
chemotherapy often induces senescence at moderate doses and apoptosis at higher ones.
Senescence markers have also been found in biopsy from patients undergoing
chemotherapy.
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CHAPTER 2.

PHARMACOKINETICS OF EDL-291
2.1. Introduction

As described in 1.2.5, previous studies show that replacement of the A-rings
catechol group in EDL-155 with dimethoxy may decrease the clearance (CL) by blocking
the metabolic “soft-spot”. However, the increase of LogP caused by this modification
may also decrease the brain penetration [63].
Based on these findings, efforts were made by our collaborating laboratories to
decrease the LogP, block the metabolic “soft-spot,” and increase antiglioma potency at
the same time. EDL-291, i.e., 6,7-dimethoxy-1-[4- (4-methoxypyridin-3-yl) phenyl]
methyl-1,2,3,4-tetrahydroisoquinoline, is one of the best EDL-155 analogs to achieve
these goals. Chemical structure and selected physiochemical properties of EDL-291 are
shown in Figure 2-1. By also replacing the C phenyl ring with 4-methoxypyridin while
blocking the A-rings catechol group, the LogP is reduced rather than increased. A pilot
study indicates that at 10 min after intravenous (though vena cava) injection of 10 mg/kg
to rats, the brain concentration of EDL-291 is higher than that of EDL-155 (2.45 vs. 1.16
ng/mg). In addition, the EC50 on C6 rat glioma cells is also reduced from 1.5 to 0.6 mM
[95]. Therefore, EDL-291 could be a promising drug candidate for glioma treatment. And
this warrants a detailed, preclinical pharmacokinetic characterization.
2.2. Materials and Methods
2.2.1. Materials
Ammonium acetate (ACS), HPLC grade acetonitrile and HPLC grade water were
purchased from Fisher Scientific (Fair Lawn, NJ). Heparinized drug free rat plasma (Cat#
ES1009P, Lot# 341234-P) was obtained from Biomeda (Foster City, CA). Test
compounds EDL-115 (internal standard for EDL-155), EDL-155, EDL-291 (internal
standard for EDL-313 and EDL-291MD), EDL-291MD, EDL-313 (internal standard for
EDL-291) and EDL-323 were synthesized in Dr. Duane Miller’s laboratory.
2.2.2. LC/MS/MS method
The LC/MS/MS system was composed of an AB Sciex (Foster City, CA) API
3000 tandem mass spectrometer and Shimadzu (Columbia, MD) LC-10ADvp pumps, and
a LEAP (Carrboro, NC) HTS PAL autosampler. Data were processed using Analyst®
software 1.4.2 (AB Sciex, Foster City, CA).
Chromatographic separation was performed using a Cadenza CD-C18 column
(100 × 2.0mm, 3 μm, purchased from Silvertone Sciences, Philadelphia, PA). Mobile
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Figure 2-1.

Structure and selected physiochemical properties of EDL-291

Exact mass and cLogP are calculated by ChemDraw Ultra 12.0 (CambridgeSoft
Corporation, Cambridge, MA). All other values are calculated by Marvin Calculator
Plugins (ChemAxon Kft., Hungary).
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phase, consisting of A (10mM NH4Ac in HPLC grade water, pH7.4) and B (acetonitrile),
was delivered at 0.5 mL/min. The total run time was 3.5 min. Gradient elution began at
30% B and was held for 1 min, then increased to 70% B over 1 min, decreased to 30% B
over 1 minute, and finished at 30% B for 0.5 min.
The mass spectrometer was operated in the positive electrospray ionization (ESI)
mode (TurboIonSpray) with the following parameters: ionspray voltage (IS) 1500 V,
nebulizing gas (NEB) 14.0, curtain gas (CUR) 14.0, source temperature (TEM) 550.0 °C,
collision-activated dissociation (CAD) gas 7.0, declustering potential (DP) 76.0 V,
focusing potential (FP) 150.0 V, entrance potential (EP) 10.0 V, collision energy 31.0 V,
collision cell exit potential (CXP) 18.00 V, deflector (DF) –200 V, channel electron
multiplier (CEM) 2200 V, and turbo gas (GS2) 7.0 L/min.
The MS/MS measurements were performed in multiple reaction monitoring
(MRM) mode. The molecule ions [M + H] + selected in Q1 were subjected to
collision-activated dissociation by N2 in the collision cell (Q2), and the product ions were
monitored by scanning the third quadrupole (Q3). Monitored MRM transition were
332.4167.2 for EDL-155, 361.0 168.1 for EDL-115, 391.2→200.1 for EDL-291,
375.0200.1 for EDL-291MD, 395.0→202.2 for EDL-313, and 379.2→202.2 for
EDL-323.
For metabolite identification, a slow gradient and Q1 scan were used. Then the
total ion current (TIC) chromatograph was extracted using the molecular weight of each
putative metabolite ± 0.5 amu. The possible metabolites found were further verified by
neutral loss, precursor, and/or MRM scan.
2.2.3. Animals
Male Sprague-Dawley rats weighing between 250 and 275 grams were purchased
from Charles River Laboratories (Wilmington, MA) and maintained in the animal facility
at UTHSC. Rats were fed ad libitum on normal laboratory diet and water. A 12 hr
light-dark cycle and ambient temperature of 25 °C were maintained. Rats for the
peripheral pharmacokinetic study were individually housed in the metabolism cages and
rats for the CNS pharmacokinetic study were individually housed in regular plastic cages.
Rats bearing both jugular and femoral vein catheters were used for the peripheral
pharmacokinetic study after intravenous bolus injection (n = 6). Rats bearing only jugular
vein catheters were used for the CNS pharmacokinetic study after intravenous bolus
injection (n = 9) or for the peripheral pharmacokinetic study after oral gavage (n = 5).
The patency of the jugular vein and femoral vein catheters was maintained every other
day with heparinized glycerol solution (500 IU heparin/mL final solution in 75%
glycerol) according to vendor’s instructions.
Male C57BL/6J mice weighing between 25 and 35 grams were purchased from
The Jackson Laboratory (Bar Harbor, ME) and maintained in the animal facility at
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UTHSC. Mice were fed ad libitum on normal laboratory diet and water. A 12 hr
light-dark cycle and ambient temperature of 25 °C were maintained.
2.2.4. Drug solution
EDL-291 was dissolved in sterile normal saline at 10 mg/mL concentration.
2.2.5. Plasma protein binding
Pooled rat plasma or pooled human plasma from healthy donors was spiked with
aqueous EDL-291 stock solution to the desired concentrations (5μg/mL and 10μg/mL).
All samples were incubated at 37 °C for 1 h before being centrifuged in Microcon
Ultracel YM-30 (molecular weight cut-off 30,000 Da; Millipore, Billerica, MA) at room
temperature, 10,000 g, for 15 min. Filtrate or non-filtrated spiked plasma was mixed with
4 volume of ice-cold acetonitrile and then centrifuged at 4 °C, 10,000 g, for 5 min. 10 µL
supernatant from each sample was injected into LC/MS/MS, respectively. Phosphate
buffered saline (PBS) was also treated in the same way to determine the effect of
non-specific binding. The plasma protein binding (PPB) was calculated as follows:
PPB (%) = [(1 - Iu / It ) - (1 - Icu / Ict )] × 100%
where Iu, It, Icu, and Ict refer to EDL-291 peak area in filtrate of spiked plasma sample,
non-filtrated spiked plasma sample, filtrate of spiked PBS sample, and non-filtrated
spiked PBS sample, respectively.
2.2.6. Erythrocyte partitioning
The method used was adopted from the depletion method reported by Yu et al.
[96]. Fresh human blood from healthy male donors was spiked to 500 nM EDL-291
concentration. Fresh human plasma prepared from the same batch of fresh whole blood
was used as a reference and treated in the same way. The reference plasma volume was
identical to the whole blood volume. Both sample tubes were gently mixed and then
incubated at 37 °C for up to 2 h. During the incubation, at 0, 60, and 120 min, a 200 μL
aliquot of incubated whole blood was removed from each sample tubes and centrifuged
in Microtainer® tubes with lithium heparin and plasma separation gel (Catalog # 365958,
BD, Franklin Lakes, NJ) at 10,000 g, 4 °C for 2 min. A 50 μL aliquot of generated
plasma was transferred into a new tube. At each of these time points, a 50 μL aliquot of
incubated reference plasma sample was also sampled and transferred into a new tube. 200
µL of ice-cold acetonitrile was then added to each of 50 μL plasma or whole blood
samples. The resulting mixture was vortexed and centrifuged at 10,000 g, 4 °C for 10
min. 10 µL of the supernatant was injected for LC/MS/MS analysis. The red blood cells
partition coefficient of a given compound, KRBC/PL, is the ratio of the concentration of that
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compound in the red blood cells to concentration of that compound in plasma. KRBC/PL,
can be determined from following equation:
KRBC/PL =

1 IREF
PL
ቆ
-1ቇ +1
H IPL

where H = hematocrit value, IREF
PL = peak area of EDL-291 in reference plasma, and
IPL = peak area of EDL-291in equilibrating plasma from whole blood.
2.2.7. Stability in whole blood
Fresh blood from a male SD rat was spiked to 1μM EDL-291 or EDL-155
concentration and then incubated in a shaker at 37 °C, 250 rpm for up to 3 h. During the
incubation, a 30 μL aliquot was removed at 0, 60, 120, and 180 min, respectively. 270 µL
of distilled water was added first; then the mixture was vortexed for 30 s, kept at room
temperature for 15 min, and then 1200 µL ice-cold acetonitrile with 0.1% formic acid
(v/v) was added to the aliquot and kept at 4 °C for 15 min. The resulting mixture was
vortexed for 30 s and then centrifuged at 10,000 g, 4 °C for 10 min. A 100 µL of the
supernatant was mixed with 100 µL of distilled water in a glass vial, and then was kept
at -20 °C until analysis next day. Then 10 µL was injected for LC/MS/MS analysis. The
parent compound remaining in the incubation mixture at various time points was
determined by comparing peak area of those time points to that of 0 min sample.
2.2.8. Stability to pulmonary metabolism
A 4 × NADPH regenerating system master mix was prepared by mixing BD
Gentest NADPH-regenerating system solution A (20 × ) (Catalog Number: 451220),
solution B (100 × ) (Catalog Number: 451200), and an appropriate volume of
HPLC-grade water. Test compound stock solution was prepared at 1 mg/mL in HPLC
grade water. Male SD rat pulmonary microsomes (10 mg/mL) were purchased from
XenoTech (Lenexa, Kansas). The final concentration of each component in the
incubation system was 50 μM drug, 2.0 mg/mL microsomes, 1.3 mM NADP+, 3.3 mM
glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase, 3.3 mM magnesium
chloride, and 50 mM pH 7.4 potassium phosphate buffer. The total volume of each
reaction was 500 µL. The reaction was initiated by adding microsomes and was
incubated in a 37 °C CO2 incubator. 100 µL mixtures were removed from one of the
reactions at 0 and 120 min after start and then mixed thoroughly with 100 µL ice-cold
acetonitrile containing IS. These samples were centrifuged at 10,000 g for 30 min, and
the supernatant was injected into LC/MS/MS directly.
The parent compound remaining in the incubation mixture at various time points
was determined by comparing the internal standard normalized peak area of the parent
compound (Icompound/IIS) to that of 0 min sample as follows:

29

Percent of remaining (%) = (Icompound/IIS) t / (Icompound/IIS) 0 × 100%
where (Icompound/IIS )t and (Icompound/IIS )0 represent the internal standard normalized peak
areas of the parent compound measured at various time points and 0 min, respectively.
2.2.9. Pharmacokinetic sampling and processing
2.2.9.1. Peripheral pharmacokinetics
2.2.9.1.1. Intravenous bolus injection. EDL-291 was administered (10 mg/kg) to
SD rats (n = 6) by intravenous bolus via the femoral vein catheter. Blood (100 µL) was
collected into Microtainer® tubes with lithium heparin and plasma separation gel from the
jugular vein catheter at 5, 15, 30, 45, 60, 75, 90, 120, 180, 240, 360, 480, 600, and 1440
min after dosing. Samples were centrifuged at 10,000 g, 4 °C for 2 min. Plasma was
stored at -80 °C until analysis. Drug-free urine and feces were collected the day before
the drug administration. At 24 hr post-dose, the feces were carefully collected into 50 mL
polypropylene centrifuge tubes and weighed. The volume of the total urine sample was
obtained by subtracting the bottle weight from the total weight. All the feces and urine
samples were then stored at -80 °C until analysis using LC/MS/MS.
2.2.9.1.2. Oral gavage. EDL-291 was administered (40 mg/kg) to SD rats (n = 5)
by oral gavage with an18G stainless steel feeding needle. Blood (100 µL) was collected
into Microtainer® tubes with lithium heparin and plasma separation gel from the jugular
vein catheter at 20, 40, 60, 80, 100, 120, 180, 240, 360, 480, 600, and 1440 min after
dosing. Samples were centrifuged at 10,000 g, 4 °C for 2 min, and the plasma was stored
at -80 °C until analysis.
2.2.9.2. CNS pharmacokinetics
2.2.9.2.1. Rat intravenous bolus injection. EDL-291 was administrated (10
mg/kg) to SD rats (n = 9) by intravenous bolus via the jugular vein catheter. Rat was then
anesthetized by 0.65 ml/kg ketamine/xylazine premix and perfused transcardially by
normal saline for 2 min. Rat brains were collected at 20 min (n = 5), 90 min (n = 2), and
180 min (n = 2) post-dose, respectively after perfusion. These samples were kept at
-80 oC until analyzed by LC/MS/MS.
2.2.9.2.2. Mouse subcutaneous injection. EDL-291 was administered (50 mg/kg)
to C57BL/6J mice (n = 12) by subcutaneous injection. Two of these mice were
anesthetized by ketamine/xylazine at 5, 15, 25, 55, 85, or 175 min post-dose,
respectively. The blood samples were collected by cardiac puncture at 10, 20, 30, 60, 90,
and 180 min post-dose then centrifuged at 10,000 g, 4 °C for 2 min, and the plasma was
stored at -80 °C until analysis. The brains were collected after 5 min of transcardial
perfusion and kept at -80 oC until analyzed by LC/MS/MS.
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2.2.9.3. Sample preparations
2.2.9.3.1. Plasma sample preparations. 200 µL of ice-cold acetonitrile and 20 µL
of IS (internal standard solution) were added to each of 50 μL plasma samples. The
resulting mixture was vortexed and centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the
supernatant was injected for LC/MS/MS analysis.
2.2.9.3.2. Feces sample preparations. 4 ml per gram of acetonitrile was added to
feces; then the mixture was homogenized by PowerGen 125 handheld homogenizer
(Fisher Scientific, Fair Lawn, NJ) for 30 s at maximal speed. 250 µL homogenate was
transferred to another 2 mL tube and 20 µL of IS was added. The resulting mixture was
vortexed and centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the supernatant was
injected for LC/MS/MS analysis.
2.2.9.3.3. Urine sample preparations. 200 µL of ice-cold acetonitrile and 20 µL
of IS (internal standard solution) were added to each of 50 μL urine samples. The
resulting mixture was vortexed and centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the
supernatant was injected for LC/MS/MS analysis.
2.2.9.3.4. Brain sample preparations. 1 mL per gram of HPLC grade water was
added to the collected brains; then the mixture was homogenized by PowerGen 125
handheld homogenizer for 30 s at maximal speed. 100 µL homogenate was transferred to
another 2 mL tube; then 50 µL of IS and 500 µL of ice-cold acetonitrile were added. The
resulting mixture was vortexed and centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the
supernatant was injected for LC/MS/MS analysis.
2.2.10. Pharmacokinetics data analysis
The in vivo pharmacokinetic data of EDL-291 were processed using WinNonlin™
Professional version 5.2 (Pharsight Corporation, Mountain View, CA) for the estimates
of pharmacokinetic parameters based on noncompartmental analysis (NCA), or
user-defined three-compartment model (Figure 2-2). WinNonlin codes for the
user-defined model are shown in Figure 2-3.
The user defined three-compartment model was used to fit simultaneously the
naïve averaged EDL-291 plasma concentration data from the intravenous bolus injection
peripheral pharmacokinetics study mentioned in 2.2.9.1.1 and naïve pooled and averaged
brain concentration data from the CNS pharmacokinetics study mentioned in 2.2.9.2.1. A
two-compartment model analysis (without the brain compartment) was performed first to
get the initial estimate of parameters. This approach is similar to the one used by Rai et
al. [97]. Nelder-Mead method with iterative reweighting (1/Ŷ2) was used in minimization
process.
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Figure 2-2. Three-compartment user-defined model for simultaneous fitting of
plasma and brain concentration of EDL-291 after intravenous bolus injection
Boxes represent compartments. Arrows represent direction of mass transfer. The rate
constants (k10, k12, k21, k13, and k31) are shown beside the corresponding mass transfer
arrows.
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MODEL
remark ******************************************************
remark Developer: Fei Ma
remark
remark Model Version:
1.0
remark ******************************************************
remark Brain/Plasma Conc, Clear from central compt
remark - define model-specific commands
COMMANDS
NFUNCTIONS 2
NCONSTANTS 1
NDERIVATIVES 3
NPARAMETERS 6
PNAMES 'k10', 'k12','k13','k21','k31','V1'
END
remark - define temporary variables
TEMP
Dose = CON(1)
END
remark - define differential equations starting values
START
Z(1) = Dose/V1
Z(2) = 0
Z(3) = 0
END
remark - define differential equations
DIFFERENTIAL
DZ(1) = k21*Z(2)+k31*Z(3)-(k10+k12+k13)*Z(1)
DZ(2) = k12*Z(1)-k21*Z(2)
DZ(3) = k13*Z(1)-k31*Z(3)
END
remark - define algebraic functions
FUNCTION 1
F= Z(1)
END
FUNCTION 2
F= Z(3)
END
remark - define any secondary parameters
remark - end of model
EOM

Figure 2-3.
Figure 2-2

WinNonlin codes for the three-compartment user-defined model in
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2.3. Results
2.3.1. Plasma protein binding
EDL-291 was extensively bound to plasma proteins with percent bound values of
60.0, 54.4, 56.4, and 58.9 at concentrations of 5 μg/mL in rat plasma, 10 μg/mL in rat
plasma, 5 μg/mL in human plasma, and 10 μg/mL in human plasma, respectively.
2.3.2. Erythrocyte partitioning
In order to understand erythrocyte accumulation of EDL-291 and EDL-155,
partition coefficient KRBC/PL was estimated for both compounds. The calculated KRBC/PL
of EDL-291 after 0, 60, and 120 min incubation are 0.2, 0.9, and 0.6, respectively. In
contrast, the KRBC/PL values of EDL-155 at same time points are 5.6, 8.6, and 1.4,
respectively (Figure 2-4). Therefore, EDL-291 does not accumulate in erythrocytes at the
tested concentration, while EDL-155 does.
2.3.3. Stability in whole blood
As shown in Figure 2-5, EDL-291 is stable in whole blood at the concentrations
tested, while the last generation compound EDL-155 is not.
2.3.4. Pulmonary metabolic stability
As shown in Table 2-1, EDL-291 is susceptive to pulmonary microsomal
metabolism. The pulmonary stability can be improved by modification of methoxy
groups in the A-ring and C-ring.
2.3.5. Peripheral pharmacokinetics
2.3.5.1. Intravenous bolus injection
The plasma concentration versus time profile of EDL-291 (Figure 2-6) during the
sampling period demonstrates rapid elimination. The clearance (CL), volume of
distribution at steady state (Vdss), terminal half-life (t1/2), and area under the curve
(AUCiv, 0-∞) were estimated by NCA Model 201 with Linear Up/Log Down setting in
WinNonlin 5.2. The number of data points used for estimating terminal slope λz was
determined by Best Fit method in WinNonlin. The estimated individual pharmacokinetic
parameters were then summarized by built-in descriptive statistics tool in the same
software (Table 2-2). 1.2% of the dosed EDL-291 was found in urine over 24 hr
post-dose period. The identified metabolites in plasma and feces as well as the putative
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Figure 2-4.
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Incubation time (min)

120

Erythrocyte partitioning of EDL-291 and EDL-155

Concentrations of EDL-291 and EDL-155 are both 500 nM. Red blood cells partition
coefficient KRBC/PL is the ratio of the concentration of a compound in the red blood cells
to concentration of that compound in plasma.
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Figure 2-5.

Stability of EDL-291 and EDL-155 in whole rat blood

1μM EDL-291 or EDL-155 was spiked into fresh blood from a male SD rat and then
incubated in a shaker at 37 °C, 250rpm for up to 3 h.
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Table 2-1.
Percentage of parent compounds remaining after 2 hr incubation with
rat pulmonary microsomes
ID

Percentage of parent
compounds remaining
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Figure 2-6.
of EDL-291

Plasma concentration-time profile in SD rats after 10 mg/kg intravenous bolus injection or 40 mg/kg oral gavage

Intravenous bolus (IV) injection: n = 5 at 5 min, 360 min, and 1440 min; n = 1 at 600 min; n = 6 at all other time points. Oral gavage
(PO): n = 4 at 80 min and 120 min; n = 5 at at all other time points. The error bars are standard deviations.
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Table 2-2.
Pharmacokinetic parameters of EDL-291 in male SD rats after
intravenous bolus injection
Subject
No. 2
No. 3
No. 4
No. 5
No. 6
No. 7
Geometric Mean
CV (%)

CL
(mL/min/kg)
190
252
294
167
215
166
209
23.7

Vdss
(L/kg)
28.6
49.4
60.7
26.3
36.4
14.4
32.5
46.6
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Terminal t1/2
(min)
465
322
338
352
492
92.0
305
41.3

AUCiv, 0-∞
(min·mg/L)
52.6
39.7
34.0
59.8
46.5
60.3
47.8
21.9

pathways are shown in Figure 2-7.
2.3.5.2. Oral gavage
The plasma concentration-time profile after oral gavage is also shown in Figure
2-6. Oral clearance (CLoral), oral volume of distribution during terminal phase (Vdz, oral),
terminal half-life (t1/2,z), area under the curve (AUCpo, 0-∞), maximum plasma
concentration (Cmax), and time to reach maximum plasma concentration (tmax) were
estimated by NCA Model 200 with Linear Up/Log Down setting in WinNonlin 5.2. The
number of data points used for estimating terminal slope λz was determined by Best Fit
method in WinNonlin. The estimated individual parameters were then summarized by
built-in descriptive statistics tool in the same software (Table 2-3). The absolute
bioavailability was calculated as ratio of dosed normalized geometric mean of AUCpo, 0-∞
and AUCiv, 0-∞.
2.3.6. CNS pharmacokinetics
2.3.6.1. Rat intravenous bolus injection
The rat brain and plasma concentration profile was shown in Figure 2-8. The
AUCbrain20 -180 min was estimated at 361 min•mg/L by noncompartmental analysis of the
naïve pooled sparse sampling brain concentration data using WinNonlin 5.2 NCA Model
201 with Linear Interpolation setting. By using the plasma concentration data generated
in peripheral pharmacokinetics experiment after intravenous bolus, AUCplasma20 - 180 min ,
the geometric mean of individual plasma EDL-291 exposure during the same time, was
estimated at 23.7 min•mg/L. Thus the rat brain to plasma AUC ratio was estimated at
14.0.
The averaged brain and plasma concentrations were also simultaneously fitted
(Figure 2-9) into the three-compartment model shown in Figure 2-2. The final estimates
of parameters for the model parameters are k10 = 0.164 ± 0.0246 min-1 (estimate ±
standard error), k12 = 0.0265 ± 0.00606 min-1, k13 = 0.736± 0.419 min-1, k21= 0.00199 ±
0.000320 min-1, k31 = 0.0817 ± 0.0404 min-1, and V1 = 1.08 × 103 ± 195 mL/kg.
2.3.6.2. Mouse subcutaneous injection
The mice brain and plasma concentration profile was shown in Figure 2-10. The
mice AUCbrain10 -180 min and AUCplasma10 -180 min were estimated at 150 min·mg/L and 36.9
min·mg/L, respectively by noncompartmental analysis of the naïve pooled sparse
sampling data using WinNonlin 5.2 NCA Model 200 with Linear Interpolation setting.
Thus the mice brain to plasma AUC ratio was estimated at 4.07. In addition, the mice
subcutaneous clearance was estimated to be 1.16 L/min/kg.
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Figure 2-7.

Metabolites of EDL-291 in rat plasma and feces

EDL-291 metabolites from both phase I and phase II xenobiotic metabolism are found in plasma and feces of male SD rats that
received intravenous dosing.
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Table 2-3.

Pharmacokinetic parameters of EDL-291 in male SD rats after oral gavage
Subject

CLoral
(mL/min/kg)

Vdz, oral
(L/kg)

No. 1
No. 2
No. 2
No. 4
No. 5
Geometric Mean
CV (%)
Median
Range

492
510
740
486
409
517
23.7
-

93.6
52.4
65.4
82.6
56.9
68.5
24.8
-

Terminal t1/2
(min)
132
71.3
61.3
118
96.5
91.9
31.2
-

Cmax
(ng/mL)

tmax
(min)

504
457
239
599
689
504
450

40
20
100
40
40
40
80

AUCpo, 0-∞
(min·mg/L
)
81.2
78.5
54.0
82.4
97.8
77.4
20.0
-

Note: Bioavailablity (F) = ( AUCpo, 0-∞ / Dosepo ) / ( AUCiv, 0-∞ / Doseiv) × 100%= ( 77.4 / 40 ) / ( 47.8 / 10 ) × 100% = 40.4 %
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AUCbrain/AUCplasma20-180min = 14.0
Brain

Plasma

Figure 2-8.

Brain and plasma concentration-time profile after 10 mg/kg intravenous bolus injection to SD rats

Plasma: n = 5 at 5 min, 360 min, and 1440 min; n = 1 at 600 min; n = 6 at all other time points. Brain: n = 5 at 20 min, n = 2 at both 90
min and 180 min. The error bars are standard deviations.
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Brain

Plasma

Figure 2-9. Simultaneous fitting of rat brain and plasma concentration after 10 mg/kg intravenous bolus injection to the
three-compartment user-defined model
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AUCbrain/AUCplasma10-180min = 4.07

Brain

Plasma

Figure 2-10. Brain and plasma concentration-time profile after 50 mg/kg subcutaneous injection to mice
Plasma: n = 1 at 30 min; n = 2 at all other time points. Brain: n = 2. The error bars are standard deviations.
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2.4. Discussion
Pharmacokinetic study is an integral part of the current drug development
paradigm, playing an important role in various developmental stages. In the early drug
development process, information obtained from pharmacokinetic study can provide
valuable feedback for lead optimization and drug candidate selection [98]. The subject of
the preclinical pharmacokinetics investigation presented in this chapter is the
tetrahydroisoquinoline analog EDL-291, a result from DMPK-guided structure
modification (i.e., blocking the metabolic hot spots and lowering cLogP) of lead
compound EDL-155.
As expected, total body clearance of EDL-291 in male SD rats (209 mL/min/kg)
is 39% lower than that of EDL-155 (343 mL/min/kg). However, the former value is still
almost 4 times higher than rat hepatic blood flow (55.2 mL/min/kg) and approaches
cardiac output (296 mL/min/kg) [99]. For most drugs, the liver and kidney are the two
most important eliminating organs. Therefore, total clearance (CL) can usually be
approximate by hepatic clearance (CLh) plus renal clearance (CLr) (Figure 2-11). The
renal clearance of EDL-291 can be ignored, since the fraction excreted unchanged in
urine (fe) is only 0.012. Hepatic clearance cannot be larger than liver blood flow (Qh)
since the hepatic extraction ratio (ERh) cannot be larger than 1. So the elimination of
EDL-291 far exceeds the capacity of liver. Thus, there must be either some experimental
artifacts which can lead to overestimating total clearance of EDL-291 or some
extrahepatic mechanisms that contribute substantially to the elimination.
The first extrahepatic mechanism deserving consideration is the pulmonary
metabolism [100-102]. The lung contains various CYP450 enzymes as well as phase II
drug metabolism enzymes [103-108]. It has the potential of metabolizing many foreign
chemicals to a vast array of metabolites with different pharmacological and toxicological
properties [100, 102, 109, 110]. Intravenously dosed drugs are subject to pulmonary
metabolism before entering the liver. Since lungs accept total cardiac output, which is 5
times higher than hepatic blood flow in rats, if the pulmonary extraction ratio is same as
hepatic extraction ratio, the rat lung clearance could be 5 times higher than the hepatic
CL = CLh + CLr

CLh ≈CL-CLr
=Qh*ERh < Qh

CLr=fe*CL

Figure 2-11. The usual relationship between total body clearance (CL), hepatic
clearance (CLh), renal clearance (CLr), and liver blood flow (Qh)

45

clearance. As evidenced by the pulmonary microsomal stability experiment, EDL-291 is
susceptive to pulmonary metabolism. The hot-spots for pulmonary metabolism are the
methoxy groups in A-ring and C-ring since modification of these groups can increase the
stability to pulmonary microsomes.
Another important extrahepatic mechanism is metabolism or chemical
degradation in the blood. Various drug metabolizing enzymes are located in either blood
cells or plasma, and contribute to the elimination of dozens of structurally diverse drugs
[111, 112]. Metabolism and degradation in blood is apparently not limited by the hepatic
blood flow. However, the whole blood incubation experiment demonstrated that
EDL-291 is stable for 3 hr in blood. Thus the contribution of blood
metabolism/degradation to total body clearance of EDL-291 is negligible.
A well-known artifact that can cause extraordinarily high clearance value is drug
accumulation in erythrocytes [113]. Clearance is defined as the volume of blood
irreversibly cleared of drug per unit of time. The total clearance value can be calculated
as the dose divided by AUC in blood. For most drugs, blood concentration is close to
plasma concentration, and plasma is easier to handle. Thus clearance of a drug is usually
calculated from plasma drug concentration data instead of the whole-blood concentration
data. This common practice is also used in this study. However, if the compound is
accumulated in erythrocytes, i.e., the blood concentration is higher than plasma
concentration, the clearance will be overestimated. Since the result of the erythrocyte
partitioning experiment showed that EDL-291 does not accumulate in erythrocytes, the
high clearance is not caused by this artifact.
Therefore, the major contributor to the high clearance of EDL-291 is extensive
lung metabolism. Measurement of the afferent-efferent arterial (pulmonary artery vs.
aorta) concentrations in steady states during a long intravenous infusion can be used in
future study to confirm this finding in vivo [100, 102]. Comparing AUC after intravenous
or intra-aortic short-term infusion is more convenient method to examine effect of lung
on drug disposition. However, in some case, lung tissue may act as a deep compartment,
which drugs will bind to and will not be released before end of blood sampling [100,
102]. The afferent-efferent concentrations measurement can assure that the binding sites
in lungs are saturated after long infusion and thus will not mistakenly count lung
retention as lung clearance. The lung clearance can be calculated as CLlung = CO* ERlung
= CO * (Cpa - Caorta) / Cpa, where CLlung, ERlung , CO, Cpa and Caorta refer to lung clearance,
lung extraction ratio, cardiac output, drug concentration in pulmonary artery and drug
concentration in aorta in this method, respectively. The lung clearance is a well-known
exception to additivity of organ clearance [102]. But the ratio CLlung/ CL can still be used
to express the relative contribution of lung to the total clearance.
It can be speculated that intra-arterial injection of EDL-291 will lead to higher
systemic exposure by avoidance of pulmonary first-pass effect. According to principle of
diffusion, brain exposure will also be increased. If EDL-291 is injected through a
microcatheter [114] to the rat internal carotid artery branch that supplies blood to brain,
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its brain exposure of will be further increased since almost all the injected compound will
be presented to BBB without loss due to clearance by lung, liver or kidney.
EDL-155 was included as a control in the above-mentioned pulmonary
microsomal stability, whole blood stability, and erythrocyte partitioning experiments. The
results suggest that blood metabolism/degradation and erythrocyte accumulation
contributed to the high clearance value of that compound.
Due to the difficulties in collecting CSF and the nature of early phase brain
pharmacokinetic research, brain homogenate concentrations of EDL-291were measured
in this study. AUCbrain/AUCplasma ratio of 14.0 in rats and 4.07 in mice indicates a high
brain penetration of EDL-291. A three-compartment pharmacokinetic model was
successfully developed to fit EDL-291 plasma and brain homogenate concentrations
simultaneously using WinNonlin software.
Plasma protein binding of EDL-291 is around 60% at 5 μg/mL and 10 μg /mL
concentration levels. Lowered plasma protein binding may be one of the reasons for
improved brain penetration since the fraction of free drug available for BBB diffusion is
increased. The bioavailability of EDL-291 after oral gavage is 42%. This indicates that
oral dosing is feasible for this compound.
Both phase I and phase II metabolites of EDL-291 were found in plasma and
feces. COMT, responsible for methylation of the A-ring catechol of EDL-155, might be
able to convert the A-ring didemethylation metabolite of EDL-291 back to the
monodemethylation metabolite. As reported before, the most abundant EDL-155
metabolite is formed by C-ring hydroxylation [65]. In EDL-291 structure modification in
C-ring seems to have successfully blocked that reaction.
In conclusion, preclinical pharmacokinetic studies of EDL-291 were conducted in
mice and rats following intravenous, oral, and subcutaneous administrations. EDL-291
demonstrated lower clearance and improved brain penetration compared to the last
generation compound EDL-155. EDL-291 has a low fraction of renal elimination, but the
total clearance is still higher than liver blood flow. The likely mechanism of this high
clearance value is not the red blood cell distribution or metabolism/degradation in blood.
EDL-291 is rapidly and extensively metabolized by the lung microsomes, indicating that
lung metabolism may cause this phenomenon.
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CHAPTER 3.

PHARMACOKINETICS OF EDL-323
3.1. Introduction

As shown in Chapter 2, EDL-291 was extensively metabolized by the lung
microsomes, and demonstrated high clearance. For developing an antiglioma agent with
better in vivo stability, EDL-323, i.e., 4-chloro-3- (4- {2H,5H,6H,7H,8H- [1,3] dioxolo
[4,5-g] isoquinolin-5-ylmethylphenyl) pyridine, a derivative of EDL-291, was
synthesized in Dr. Duane Miller’s laboratory by modification of pulmonary metabolic
“soft spots.” Chemical structure and selected physiochemical properties of EDL-323 are
shown in Figure 3-1.
As shown in Table 2-2, EDL-323 has higher stability to rat pulmonary
microsomes when compared to EDL-291. The objective of the experiments in this
chapter was to examine the in vivo pharmacokinetic properties of EDL-323 in rats
following both intravenous and oral administrations, which were used to provide
feedback information for further antiglioma drug development decisions.
3.2. Materials and Methods
3.2.1. Materials
Ammonium acetate (ACS), HPLC grade acetonitrile and HPLC grade water were
purchased from Fisher Scientific (Fair Lawn, NJ). Compounds EDL-323 and EDL-313
(internal standard for EDL-323) were synthesized in Dr. Duane Miller’s laboratory.
3.2.2. LC/MS/MS method
The LC/MS/MS system was composed of an Applied Biosystems Sciex (Foster
City, CA) API 3000 tandem mass spectrometer, and Shimadzu (Columbia, MD)
LC-10ADvp pumps with a LEAP (Carrboro, NC) HTS PAL autosampler. Data were
processed using Analyst software 1.4.2. Chromatographic separation was performed
using a Cadenza CD-C18 column (100 × 2.0mm, 3 μm, purchased from Silvertone
Sciences, Philadelphia, PA). The mobile phase consisting of A (10mM NH4Ac in HPLC
grade water, pH7.4) and B (acetonitrile) was delivered at 0.5 mL/min. The total run time
was 3.5 min. Gradient elution began at 30% B and was held for 1 min, then increased to
70% B over 1 min, decreased to 30% B over 1 min, and finished at 30% B for 0.5 min.
The mass spectrometer was operated in positive ESI mode with the following
parameters: ionspray voltage (IS) 1500 V, nebulizing gas (NEB) 14.0, curtain gas (CUR)
14.0, source temperature (TEM) 550.0 °C, collision-activated dissociation (CAD) gas
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Molecular Weight:
378.85
Exact Mass: 378.11
cLogP: 4.44
H-bond donor: 1
H-bond acceptor: 4
Rotable bonds: 3
PSA: 43.38Å2

Figure 3-1.

Structure and selected physiochemical properties of EDL-323

Exact mass and cLogP were calculatedd by ChemDraw Ultra 12.0 (CambridgeSoft
Corporation, Cambridge, MA). All other values were calculated by Marvin Calculator
Plugins (ChemAxon Kft., Hungary).
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7.0, declustering potential (DP) 76.0 V, focusing potential (FP) 150.0 V, entrance
potential (EP) 10.0 V, collision energy 31.0 V, collision cell exit potential (CXP)
18.00 V, deflector (DF) –200 V, channel electron multiplier (CEM) 2200 V, and turbo
gas (GS2) 7.0 L/min.
The MS/MS measurements were performed under MRM mode. The molecule
ions [M + H] + selected in Q1 were subjected to collision-activated dissociation by N2 in
the collision cell (Q2), and the product ions were monitored by scanning the third
quadrupole (Q3). The monitored MRM transition values were 379.2→202.2 for EDL-323
and 395.0→202.2 for EDL-313.
3.2.3. Animals
Male Sprague-Dawley rats weighing between 250 and 275 grams were purchased
from Charles River Laboratories (Wilmington, MA) and maintained in the animal facility
of the UTHSC. All the rats (n = 4) bore both jugular and femoral vein catheters. The
patency of catheters was maintained every other day with heparinized glycerol solution
(500 IU heparin/mL final solution in 75% glycerol) according to vendor’s instructions.
Rats were fed ad libitum on normal laboratory diet and water. A 12 hr light-dark cycle
and ambient temperature of 25 °C were maintained. Rats were individually housed in
regular plastic cages.
3.2.4. Drug solution
EDL-323 was dissolved in sterile normal saline at 10 mg/mL concentration.
3.2.5. Pharmacokinetic sampling and processing
EDL-323 was administered (10 mg/kg) to SD rats (n = 4) by intravenous bolus
via the femoral vein catheter. Blood (100 µL) was collected into Microtainer® tubes with
lithium heparin and plasma separation gel (BD, Franklin Lakes, NJ, Catalog # 365958)
from the jugular vein catheter at timed intervals 2, 5, 15, 30, 45, 60, 75, 90, 120, 180,
240, 360, 480, 600, 960, and 1440 min. Samples were centrifuged at 10,000 g, 4 °C for 2
min. Plasma was stored at -80 °C until analysis.
200 µL of ice-cold acetonitrile and 20 µL of IS (internal standard solution) were
added to each of 50 μL plasma samples. The resulting mixture was vortexed and
centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the supernatant was injected for
LC/MS/MS analysis.
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3.2.6. Pharmacokinetics data analysis
The clearance (CL), volume of distribution at steady state (Vdss), terminal
half-life (t1/2), and area under the curve (AUCiv, 0-∞) were estimated by NCA Model 201
with Linear Up/Log Down setting in WinNonlin 5.2. The last 3 data points with available
concentrations were used for estimating terminal slope λz. The estimated individual
pharmacokinetic parameters were then summarized by the built-in descriptive statistics
tool in WinNonlin.
3.3. Results
The plasma concentration versus time profile of EDL-323 (Figure 3-2) during the
sampling period demonstrated rapid elimination. The secondary peak around 600 min
after dosing could be a sign of enterohepatic recirculation. The pharmacokinetic
parameters are shown in Table 3-1.
3.4. Discussion
As expected, total body clearance of EDL-323 is 38% lower than that of
EDL-291. However a pilot study showed that the brain penetration is dramatically
reduced. Therefore, other structure modifications should be tried to obtain lower
clearance but maintain the high brain penetration.
A newer derivative EDL-355 showed higher brain penetration and in vitro
efficacy in another pilot study. Thus EDL-355 will be the next candidate to be used in
future pharmacokinetics investigation.
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Figure 3-2. Plasma concentration-time profile after 10 mg/kg intravenous bolus
injection of EDL-323
N = 3 at 2 min; n =4 at all the other data points. The error bars are standard deviations.

Table 3-1.
Pharmacokinetic parameters of EDL-323 in male SD rats after
intravenous bolus injection
Subject
No. 1
No. 2
No. 3
No. 4
Geometric Mean
CV (%)

CL
(mL/min/kg)
114
136
127
155
132
12.7

Vdss
(L/kg)
9.00
19.8
9.07
7.48
10.5
50.3
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Terminal t1/2
(min)
1.07 × 103
834
776
373
713
38.0

AUCiv, 0-∞
(min·mg/L)
87.5
73.6
78.5
64.6
75.6
12.5

CHAPTER 4.

MECHANISM OF ACTION STUDY OF EDL-291
4.1. Introduction

Many EDL series of novel tetrahydroisoquinoline analogs show antiproliferative
activity on glioma cells. Since they were discovered by serendipity, the mechanism of
action was unknown for these compounds before the start of this dissertation research
project. Currently, a drug candidate with unknown mechanism is not likely to get FDA
approval [68]. Therefore, a preliminary mechanism of action study was included in this
project. EDL-291 was selected as a model compound for this study.
There are five major modes of cell death induced by chemotherapy: apoptosis,
autophagic cell death, necrosis, mitotic catastrophe, and senescence [74]. Among these,
apoptosis is the most well-known way of cell death after anticancer drug treatment.
Therefore, the role of apoptosis machinery on the activity of EDL-291 was the focus of
this study.
4.2. Materials and Methods
4.2.1. Cell cultures
Human glioma cell line U-87MG was purchased from American Type Culture
Collection (ATCC, Manassas, VA). Culture medium for this cell line was Basal Medium
Eagle with Earle's salts (BME, Mediatech, Manassas, VA) supplemented by 10% fetal
bovine serum (FBS, Sigma, St. Louis, MO), 2.2 mg/mL sodium bicarbonate (Sigma, St.
Louis, MO), 50 IU/mL penicillin (Invitrogen, Carlsbad, CA), 50 µg/mL streptomycin
(Invitrogen, Carlsbad, CA), and 50 µg/mL streptomycin (Invitrogen, Carlsbad, CA).
Human glioma cell line U251 was obtained from the National Cancer Institute (NCI,
Frederick, MD). Culture medium for this cell line was RPMI 1640 (Invitrogen, Carlsbad,
CA) supplemented by 10% fetal bovine serum, 100 IU/ mL penicillin, and 100 µg/mL
streptomycin. These cell lines were maintained in 75 cm2 culture flasks (Corning Life
Science, Lowell, MA) in a 37 °C incubator (NuAire, Plymouth, MN) containing a humid
5% CO2 atmosphere and passaged in 1:4 ratio after being washed by Dulbecco's
phosphate-buffered saline without calcium and magnesium (D-PBS, Invitrogen,
Carlsbad, CA) and dislodged by 0.25% trysin-EDTA (Mediatech, Manassas, VA) once
they reached 80% confluence.
4.2.2. Cell proliferation assay with caspase inhibitors or mitochondrial permeability
transition (MPT) inhibitors
EDL-291 was synthesized in the laboratory of Dr. Duane Miller. CellTiter 96®
AQueous Non-Radioactive Cell Proliferation (MTS) assay kit was purchased from
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Promega (Madison, WI). Pan-caspase inhibitor Z-VAD-fmk was purchased from Enzo
Life Sciences (Plymouth Meeting, PA). Caspase-3/7 inhibitor Z-DEVD-fmk was
purchased from R&D Systems (Minneapolis, MN). Caspase-8 inhibitor Z-IETD-fmk and
caspase-9 inhibitor Z-LEHD-fmk were purchased from Tocris (Ellisville, MO). MPT
inhibitor decylubiquinone (dUb) was purchased from Enzo Life Sciences.
The antiproliferative effect of EDL-291 with or without inhibitors was determined
by using MTS assay according to manufacturer’s direction. In brief, U-87MG and U251
cells were seeded at 5 × 103 cells/well in 96-well flat-bottomed plates (Corning Life
Science, Lowell, MA) and grown overnight in 200 µL aforementioned medium with 10%
FBS in a 37 °C incubator containing a humid 5% CO2 atmosphere. EDL-291 was
dissolved in sterile normal saline to get a 50mM stock solution, while caspase inhibitors
and dUb were dissolved in DMSO (Sigma, St. Louis, MO) to make stock solutions.
These stock solutions were spiked into the aforementioned medium with 2% FBS to get
drug-containing media. The DMSO concentrations were kept at less than 0.25%. Control
media were made by spiking DMSO to final concentrations that matched those in the
drug-containing media. Then the medium in the 96-well plate was replaced by 200
µL/well drug-containing medium or control medium. After the cells were incubated for
96 hr in 37 °C, 5% CO2, the consumed media were replaced by 100 µL/well fresh media
with 2% FBS. Then 20 µL/well MTS [3- (4, 5-dimethylthiazol-2-yl) -5- (3carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium] - PMS (phenazine
methosulfate) mixtures were added. After 1 hr incubation in 37 °C, 5% CO2, the
absorbance at 450 nm was measured using a DTX 880 multimode detector (Beckman
Coulter, Fullerton, CA). The absorbance of medium-only wells was subtracted from
reading of control or treated wells. The viability of control cells was considered to be
100%.
4.2.3. Caspase 3/7 activity assay
U-87MG and U251 cells were seeded at 5 × 103 cells/well in 96-well
flat-bottomed plates and grown overnight in 200 µL of the aforementioned medium with
10% FBS in a 37 °C incubator containing a humid 5% CO2 atmosphere. Then the
medium in the 96-well plate was replaced by 200 µL/well 2% FBS medium containing
10µM EDL-291 with or without dUb or control medium. After the cells were incubated
for 60 hr in 37 °C, 5% CO2, the consumed media were replaced by 100 µL/well fresh
media with 2% FBS. The luminogenic substrate and luciferase-containing buffer from the
Capase 3/7 Glo kit were mixed to prepare the reagent right before use. 100 µL prewarmed reagent was added to each well, and then the plate was put on a plate shaker for
30 min. After 60 min incubation in room temperature, the luminescence was measured by
DTX 880 multimode detector. The luminescence of medium only wells was subtracted
from reading of the control or treated wells. The blank subtracted luminescence readings
(RLU) were further normalized by absorbance at 450 nm, which was obtained from the
aforementioned MTS assay of duplicate wells.
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4.2.4. Luminex assay of activated caspase-3 and poly (ADP-ribose)
polymerase (PARP)
Human apoptosis 3-plex Luminex kit, MultiScreenHTS BV filter plates, and
vacuum manifold were purchased from Millipore (Billerica, MA). Complete MiniTM
protease inhibitor cocktail tablets were purchased from Roche Diagnostics (Indianapolis,
IN). Phosphate-buffered saline (PBS) was purchased from Invitrogen (Carlsbad, CA).
U-87MG and U251 cells were cultured in a 200 µL/well 2% FBS medium containing
10µM EDL-291 or control medium, the same as described from the caspase 3/7 activity
assay. After the cells were incubated for 72 hr or 96 hr, the consumed media were
aspirated. ¼ tablet of Complete MiniTM protease inhibitor was added to the ice-cold
Beadlyte cell signaling universal lysis buffer in the Luminex kit right before use. Then 30
µL/well lysis buffer was added, and the plates were shaken for 20 min at 4 °C. The lysate
was transferred to a pre-wetted MultiScreen HTS BV filter plate, and then was filtered by
centrifugation at 500 g for 5 min. The filtrate from the wells of the same treatment group
was combined and diluted by equal volume of PBS. 25 μL/well 1 × 3-plex [human
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), activated caspase-3, and PARP]
bead suspension and 25 μL/well diluted filtrate were added into a new MultiScreen
HTS BV filter plate pre-wetted by using vacuum manifold. The filter plate was incubated
on a plate shaker overnight at 4 °C while protected from light; then the liquid was
removed and beads were washed by using vacuum manifold. 25 μL/well of 1 × Beadlyte
biotinylated reporter was added to beads, and then the filter plate was incubated on a
plate shaker for 1 hr at room temperature. After removal of the liquid by vacuum, 25 μL
1:25 diluted Strep-PE was added to each well; then the filter plate was incubated on a
plate shaker for 30 min at room temperature. The liquid was removed again by vacuum.
The beads were resuspended by 100μl assay buffer and then analyzed on Luminex 200
system (Luminex, Austin, TX).The raw data was processed by Millipore Beadview
multiplex data analysis software, and the activated caspase-3 and PARP level were
normalized to GAPDH level.
4.2.5. Phase contrast and fluorescence microscopy
U-87MG and U251 cells were seeded at 5 × 103 cells/well in 96-well flatbottomed plates and grown overnight in 200 µL of the aforementioned medium with 10%
FBS in a 37 °C incubator containing a humid 5% CO2 atmosphere. Then the medium in
the 96-well plate was replaced by 200 µL/well 2% FBS medium containing 10µM
EDL-291 or control medium. After the cells were incubated for 60 hr in 37 °C, 5% CO2,
and pictures were taken under a phase contrast microscope. Following this, the cells were
washed by PBS, fixed by 1% paraformaldehyde for 10 min, and then stained with
Hoechst 33342 for 20 min at room temperature before pictures were taken under an
Eclipse 80i fluorescence microscope (Nikon, Melville, NY).
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4.2.6. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay
TUNEL assay was performed using a BD Pharmingen APO-BRDU kit (BD
Biosciences, San Jose, CA) according to manufacturer’s direction. Briefly, 2.34 ×106
U-87MG or U251 cells were seeded in150 cm2 culture flasks (Corning Life Science,
Lowell, MA) using the aforementioned 10% FBS media. After overnight incubation in 37
°C, 5% CO2 incubator, the consumed media were changed to drug-containing or control
2% FBS media. After 60 hr treatment, the floating cells and trypsinized adherent cells
from the same treatment were collected together. These cells were washed by PBS, fixed
by 1% paraformaldehyde, and permeabilized by 70% ethanol. Then the DNA breaks were
labeled by terminal deoxynucleotidyltransferase (TdT) catalyzed addition of bromolated
deoxyuridine triphosphates (Br-dUTP), followed by staining with fluorescein
isothiocyanate (FITC) conjugated BrdU antibody. The samples were loaded to a LSR II
flow cytometer (BD Biosciences) using 488 nm laser, and the data were processed by
FACSDiva software.
4.3. Results
4.3.1. Effect of caspase inhibitor
As shown in Figure 4-1, antiproliferative effect of EDL-291 can be partially
reversed by pan-caspase inhibitor Z-VAD-fmk and caspase-3/7 inhibitor Z-DEVD-fmk.
However, caspase-8 inhibitor Z-IETD-fmk and caspase-9 inhibitor Z-LEHD-fmk cannot
reverse the effect of EDL-291.
4.3.2. Effector caspase activation
As shown in Figure 4-2, 60 hr 10µM EDL-291 treatment can increase the activity
of caspase-3/7 in U-87MG and U251 cells. In Luminex assay, the activated caspase-3
protein as well as its product cleaved PARP are increased after 72 hr EDL-291 treatment
(Figure 4-3).
4.3.3. Cell and nucleus morphology
No change in cell morphology was found in U-87MG and U251 cells treated by
10µM EDL-291 for 60 hr (Figure 4-4). No nucleus change was found by Hoescht 33342
staining at the same time point (Figure 4-5).
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Figure 4-1. Antiproliferative effect of EDL-291 can be partially reversed by
pan-caspase inhibitor (panel A) and caspase-3/7 inhibitor (panel B), but not by
caspase-8 and 9 inhibitors (panel C)
U-87MG and U251 human glioma cells were treated by 10 μM EDL-291 with or without
caspase inhibitor for 96 hr. The cell viability was measured by MTS assay using Promega
CellTiter AQueous 96 kit. The absorbance of medium-only wells was subtracted from
reading of control or treated wells. The viability of control cells was considered to be
100%. The data shown here are representative results of 3 independent experiments. The
error bars are standard deviation of 3 replicates in the same treatment condition.
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Figure 4-2.
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EDL-291 can increase caspase-3/7 activity in human glioblastoma cells

U-87MG and U251 human glioma cells treated by 10 μM EDL-291 for 60 hr were
subjected to caspase-3/7 activity assay using Promega Caspase-Glo 3/7 kit. The data
shown here are representative results of 3 independent experiments. The error bars are
standard deviation of 3 replicates under the same treatment condition.
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Figure 4-3. Increase of activated caspase-3 and its product, cleaved poly
(ADP-ribose) polymerase (PARP) after EDL-291 treatment as measured by
Luminex multiplex immunoassay
U-87MG and U251 human glioma cells were treated by EDL-291 for 72 hr. The cell
lysate was analyzed using Millipore Human Apoptosis 3-Plex kit and Luminex 200
instrument.
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U251 Cells

U-87MG Cells

Control

EDL-291
(10μM)

Figure 4-4.

Cell morphology checked by phase contrast microscopy

U-87MG and U251 human glioma cells treated by 10 μM EDL-291 for 60 hr were
pictured under a phase contrast microscope.
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U-87MG Cells

U251 Cells

Control

EDL-291
(10μM)

Figure 4-5.
staining

Nucleus morphology checked by florescent microscopy after Hoescht

U-87MG and U251 human glioma cells treated by 10 μM EDL-291 for 60 hr were
stained with Hoechst 33342 and pictured under Eclipse 80i fluorescence microscope.
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4.3.4. DNA fragmentation
Increase of DNA fragmentation was found in U251 cells after 60 hr EDL-291
treatment as indicated by the TUNEL result, while change of DNA fragmentation in
U-87MG cells under same condition is minor (Figure 4-6).
4.3.5. Effect of MPT inhibitors
As shown in Figure 4-7, the antiproliferative effect of EDL-291 can be enhanced
rather than reversed by MPT inhibitor dUb. The caspase-3/7 activation after EDL-291
treatment also can be enhanced by dUb.
4.4. Discussion
Since antigloma activity of the EDL series of compounds was an unexpected
output in a HCV drug screening project [72]. Efforts were made by molecular docking
and various ligand binding assays to “fish” the putative molecular target directly but with
no success. Therefore, a less ambitious approach was taken, which was to first investigate
their effect of EDL series of compounds on cell death pathways. A preliminary
evaluation of the effect of EDL-291 on human glioma cell apoptosis machinery was
performed in our laboratory.
The investigation was begun with caspase inhibitor assay. The pan caspase
inhibitor can significantly reverse the effect of EDL-291 on both U-87MG and U251
human glioma cell lines, which indicates that caspases contribute to the effect of
EDL-291. Since pan caspase inhibitor also can also inhibit caspases not related to
apoptosis, a further assay with a specific inhibitor of apoptosis effector caspases-3/7 was
performed, and then followed by direct measurement of caspases-3/7 activity by
luminogenic substrate. The results confirmed activation of these effector caspases and
their involvement in the antiproliferative effect of EDL-291. An additional Luminex
assay also supported this finding.
Caspases-3/7 activation is a biochemical hallmark of apoptosis [115]. Cell and
nucleus morphology, as well as DNA fragmentation, were evaluated after 60 hr of
EDL-291 treatment, the same time point used in the caspases-3/7 activity assays.
However, no morphology change of cell or nucleus was found, and the increase of DNA
fragmentation was minor in U-87MG. The explanation could be that there is some time
delay between caspase activation and those downstream events.
As described in 1.3.3.1., effector caspases activation is catalyzed by initiator
caspases. Caspase-8 and -9 are the initiator caspases for the extrinsic and intrinsic
pathways of apoptosis, respectively (Figure 4-8). Thus specific caspase-8 and -9
inhibitors assay was performed to identify the route of apoptosis. But none of these
inhibitors could reverse the effect of EDL-291 under the condition used.
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(10μM)
8.9%
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Figure 4-6.

DNA fragmentation assay results from flow cytometric TUNEL

U-87MG or U251 cells treated by 10 μM EDL-291 for 60 hr were labeled by Br-dUTP,
then stained with FITC-conjugated BrdU antibody. X-axis is the cell count and Y-axis is
the intensity of FITC fluorescence (520 nm) that is proportional to amount of Br-dUTP
incorporation. The apoptotic cells incorporate more Br-dUTP because of existence of
abundant 3’-OH DNA ends. As shown in the figure, the percentages of apoptotic cells are
quantified as percentages of cells at the right side of P3 gate. The main peaks correspond
to the non-apoptotic cell population. The samples were measured by BD LSR II flow
cytometer using 488 nm laser, and the data was processed by FACSDiva software.

65

120

120

U-87MG Cells

100

U251 Cells

100

80

Cell Proliferation (100%)

Cell Proliferation (100%)

P<0.01

60

40

20

P<0.01
60

40

20

Control

dUb
(2µM)

EDL-291
(5µM)

U-87MG Cells

20000

EDL-291(5µM) +
dUb(2µM)

0

Control

30000

P<0.01

RFU(Caspase Glo 3/7)/A450(MTS)

0

RFU(Caspase Glo 3/7)/A450(MTS)

80

15000

10000

5000

dUb
(2µM)

EDL-291
(10µM)

U251 Cells

EDL-291(10µM) +
dUb(2µM)

P<0.05

25000

20000

15000

10000

5000
0

Control

EDL-291
(10µM)

EDL-291 (10µM) +
dUb (2µM)

0

Control

EDL-291
(10µM)

EDL-291 (10µM) +
dUb (2µM)

Figure 4-7. Antiproliferative effect of EDL-291 and caspase 3/7 activation can be
enhanced, rather than reversed by decylubiquinone (dUb)
Upper panel: U-87MG and U251 human glioma cells were treated by EDL-291 with or
without 2 μM dUb for 96 hr. The viable cell number was measured by MTS assay using
Promega CellTiter AQueous 96 kit. The reading was subtracted by media blank and then
normalized by the control. Lower panel: U-87MG and U251 human glioma cells treated
by EDL-291 with or without 2 μM dUb for 60 hr were subjected to caspase-3/7 activity
assay using Promega Caspase-Glo 3/7 kit. The data shown here are representative results
of 3 independent experiments. The error bars are standard deviation of 3 replicates under
the same treatment condition.
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Figure 4-8.
glioma cells

Apoptosis pathways and proposed model of EDL-291’s effect in

The extrinsic, intrinsic, caspase-independent and endoplasmic reticulum stress-induced
apoptosis pathways are all shown in this figure. The proposed model of EDL-291’s effect
in glioma cells are shown in red color.
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Since most chemotherapeutic drugs induce apoptosis via intrinsic route [75, 76],
and opening of mitochondrial permeability transition (MPT) pore could be an upstream
event in this route [116], the MPT pore inhibitor decylubiquinone (dUb) was used to
investigate if MPT is involved in the effect of EDL-291. This led to a surprising finding:
dUb enhances, instead of reverses, EDL-291’s effect on human glioma cells. Further
evaluation by effector caspase activity assay suggests that this effect is related to
enhancement of caspase-3/7 activation.
A recent publication about antiglioma activity of XIAP inhibitor embelin provides
a potential explanation of this finding [117]. Chemical structure of dUb is similar with
that of embelin (Figure 4-9). Therefore, dUb may also be a XIAP inhibitor and is capable
of de-inhibiting caspases. Further investigation by ligand binding assay is necessary to
test this hypothesis.
The upstream apoptotic pathway that leads to effector caspase-3/7 activation was
not successfully identified by the caspase-8/9 inhibitor assay in this study. A direct
caspase-8/9 activity assay by either luminogenic substrate or Luminex assay may be
helpful to solving this problem.
It is also possible that capsase-4 (counterpart of murine caspase-12), an
uncommon initiator caspase activated after ER stress [86], is responsible for the
caspase-3 activation after EDL-291 treatment(Figure 4-8). When ER homeostasis is
disrupted by various stimuli, unfolded proteins are accumulated in the ER, which initiate
ER stress response to enhance protein folding capabilities, reduce new protein synthesis,
and clear malformed proteins. But when this response is prolonged, it will lead to cell
death. During ER stress, ER associated procaspase-4 was released from GRP78. The
prolonged stress will also cause ER to release its calcium storage and thus increase
cytosolic Ca2+ concentration. These events enable cleavage of procaspse-4 by Ca2+
dependent cysteine proteases calpain [79, 118]. Procapase-3 then can be activated by
caspase-4 directly [87]. Multiple reports already showed that caspase-4 was activated
during ER stress in malignant human glioma [79]. Examples of drugs inducing apoptosis
via the ER stress pathway in glioma or other cancer cells include, sarco/endoplasmic
reticulum ATPase inhibitors (celecoxib, curcumin and THAP), flavonoids, N-linked
glycosylation inhibitors (tunicamycin), Golgi disruptors (brefeldin A), and proteasome
inhibitors (bortezomib) [79].
There is an unusual 60 hr time delay between beginning of EDL-291 treatment
and peaking of caspase-3 activity. This delayed apoptosis has also been observed after
radiation-induced mitotic catastrophe [119]. However, lack of nucleus morphology
change in the Figure 4-5 indicates that mitotic catastrophe did not happen. The
hypothesis that a prolonged ER stress response precedes the onset of apoptosis caused by
EDL-291 can therefore also help explain that time delay.
ER stress can lead to both apoptosis and autophagy [77]. The decrease of cell
density in treated wells in Figure 4-4 also suggests that other cell death pathways, such
as autophagy, may already have taken place before the culmination of apoptosis, which
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Decylubiquinone

Figure 4-9.

Embelin (XIAP inhibitor)

Chemical structures of decylubiquinone and embelin
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should happen after that 60 hr caspase-3 peak time. Our collaborating laboratory has
recently reported that EDL-155 can cause autophagy in Y79 retinoblastoma cells [120].
And after EDL-155 treatment, autophagosome-like double-membrane-bound large
vacuoles in cytoplasm were found in rat C6 glioma cells but not in rat normal astrocytes
[66]. As indicated by green fluorescence mitochondrial stain, the mitochondrial
membranes have coalesced into those large vacuoles in EDL-155 treated C6 cells [66],
suggesting mitophagy, i.e., specific autophagic elimination of mitochondria may have
occurred [121]. A pilot study in our laboratory shows autophagy inhibitor
3-methyladenine can partially reverse the effect of EDL-291 on human glioma cells.
Therefore, EDL-291 may cause ER stress, and the latter leads to both apoptosis and
autophagic cell death. A putative model of the effect of EDL-291 as well as relevant
apoptosis pathways are shown in Figure 4-7. Further investigation using ER stress
inhibitor, caspase-4 inhibitor and calpain inhibitor is needed to check the validity of this
model.
In order to find clue about the target of EDL series of compounds, a literature
search on mechanisms of action of other isoquinoline derivatives with antiglioma activity
was conducted. Tetrahydropapaveroline, the structure of which is very similar to that of
EDL-155, can cause oxidative DNA damage and JNK/MAPK mediated cell death in rat
C6 glioma cells [122]. However, this mechanism depends on the catechol moieties in the
structure of tetrahydropapaveroline. The catechol moiety can be found in structure of
EDL-155 but not in the structure of EDL-291. The fact that EDL-291 has lower EC50
than EDL-155 is apparently against this oxidative damage mechanism.
Papaverine can also inhibit growth of rat C6 glioma cells [123]. There are two
possible mechanisms: increase of intracellular cAMP concentration by inhibiting
phosphodiesterase (PDE) 3 and 4 [124, 125], and inhibition of mitochondria respiration
[126]. Increased cAMP level is a proapoptotic signal in multiple cancer cell lines and
may promote differentiation of astrocyte, while low levels of cAMP promote glioma
formation in neurofibromatosis-1 (NF1) genetically engineered mice [127]. Another
PDE4 inhibitor rolipram also promotes differentiation and apoptosis in A-172 human
glioma cell line [128]. However, tetrahydropapaverine and tetrahydropapaveroline,
structures of which closely mimic those of EDL-291 and EDL-155, respectively, have
very low PDE inhibitor activity [125]. Papaverine, tetrahydropapaverine and
tetrahydropapaveroline are all inhibitors of mitochondrial electron transport chain
complex I [129, 130]. In the other hand, dUb, as a substrate of complex I, can attenuated
the inhibition caused by the potent complex I inhibitor rotenone [131]. Therefore, at least
for EDL-291, the complex I inhibition could not be plausible mechanism, because that
mechanism is contradict to the observation in this study that dUb can enhance EDL-291’s
effect.
Another opium derived tetrohydroisoquinoline drug noscapine has antiglioma
effect both in vitro [132] and in vivo [133]. As a microtubule-interfering agent, noscapine
induces mitotic catastrophe followed by apoptosis [132]. But since no multinucleated
glioma cells were found after EDL-291 and EDL-155 treatment, microtubule-interfering
is not a plausible mechanism of the EDL series of compounds.
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In addition, tetrahydroisoquinoline alkaloid trabectedin also has antiglioma
activity in vitro [134]. Its antitumor mechanism is not fully understood. It is believed to
be able to bind the minor groove of DNA through the two fused tetrahydroisoquinoline
rings [135], which is absent in the structures of EDL series of antiglioma
tetrahydroisoquinoline derivatives.
Many other tetrahydroisoquinolines with various mechanisms of action show
activities against other types of cancer cells [136]. Tarby et al. reported a
4-phenyl-tetrahydroisoquinoline lead series has antiproliferative effect on human ovarian
cancer cells. They may act as inhibitor of human mitotic kinesin Eg5 [137]. Again, the
lack of multinucleated glioma cell after treatment ruled out this mitotic related
mechanism as the antiglioma mechanism of the EDL compounds. A series of
tetrahydroisoquinoline-based hydroxamic acid derivatives was discovered by Zhang et al.
as HDAC inhibitor with in vivo antitumor potency in a human breast carcinoma
xenograft model [138]. The carboxamide group is part of the pharmacophore [139], but
this group is not presented in the structures of EDL-291 and EDL-155. A series of
tetrahydroisoquinoline amide substituted phenyl pyrazoles are reported to be selective
Bcl-2 inhibitors [140]. However, no evidence of direct interaction between EDL-291 and
Bcl-2/Bcl-XL was found in a pilot study in our laboratory using Luminex and
fluorescence polarization techniques.
In conclusion, EDL-291 activates caspase-3/7 and PARP cleavage. The upstream
event before caspase-3 activation could be ER stress. The molecular target of EDL-291 is
still unknown. As an enhancer of EDL-291 caused capase-3/7 activation, dUb could be a
candidate as a companion drug of EDL-291 analogs in combination therapy of glioma.
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CHAPTER 5.

SUMMARY

Malignant glioma is a relative uncommon but extremely deadly disease. Each
year, more than 18,000 people are diagnosed with malignant glioma in the USA. Despite
advances in brain tumor diagnosis and treatment in the last decades, patients with
malignant gliomas, especially glioblastoma, still have a poor prognosis. Novel antiglioma
drugs are urgently needed, as chemotherapy has been established as part of standard care
for these dreadful diseases.
A novel series of tetrahydroisoquinoline derivatives with potent antiproliferative
activity against human glioma cells was identified in The University of Tennessee Health
Science Center by our collaborating laboratories as a result of scientific serendipity.
Further investigations were performed in the effort to develop a latest addition to the
current antiglioma arsenal from these compounds. Pharmacokinetics plays an important
role in the current drug discovery and development paradigm. EDL-291, a result from
DMPK-guided structure modification of last generation antiglioma
tetrahydroisoquinoline derivative lead compound EDL-155, is the subject of preclinical
pharmacokinetic characterization in this dissertation project.
In male Sprague Daley rats, after 10 mg/kg intravenous injection, total body
clearance (CL) and apparent volume of distribution at steady state (Vdss) of EDL-291
were 209 mL/min/kg (CV 23.7%) and 32.5 L/kg (CV 46.6%), respectively. 1.2% of
dosed EDL-291 was found in urine (fe) over the 24 hr post-dose period. Plasma protein
binding of EDL-291 at 5 μg/mL and 10 μg/mL concentration levels was 60.0% and
54.4%, respectively, in the rat plasma. The bioavailability (F) after oral gavage was
40.4%, which indicates this compound is orally available.
The ratio of the EDL-291 brain area under concentration curve (AUC) to plasma
AUC between 20 -180 min after intravenous injection in SD rats was 14.0. The
brain/plasma AUC ratio at 10 - 180 min after 50 mg/kg subcutaneous injection to
C57BL/6J mice was estimated at 4.07. Thus EDL-291 has high brain penetration in both
rats and mice. The rat plasma and brain concentration of EDL-291 can be fitted
simultaneously into a three-compartment model consisting of one brain compartment and
two peripheral compartments by using WinNonlin® software version 5.2.
CL of EDL-291 was 39% lower than that of EDL-155 but was still almost 4 times
higher than rat hepatic blood flow, while the small fe value indicates that renal CL was
minimal. Three possible causes were examined to decipher this phenomenon. EDL-291 is
stable in whole blood, thus metabolism or chemical degradation in blood is not a reason.
EDL-291 is also not accumulated in red blood cells, thus the high CL is not an artifact
caused by plasma sampling. On the other hand, this compound is susceptible to
pulmonary microsomal metabolism. Considering that lungs accept total cardiac output,
the major contributor to the high CL of EDL-291 is extensive lung metabolism.
EDL-323, an analog of EDL-291 with higher stability to pulmonary microsomes,
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was selected as the subject of an in vivo pharmacokinetic study. As expected, CL of
EDL-323 was 38% lower than that of EDL-291. However, a pilot study showed that the
brain penetration is dramatically reduced. Thus, further structural modifications are
required to achieve both reduced clearance and enhanced brain penetration.
Since antigloma activity of EDL compounds was an unexpected discovery in a
HCV drug screening project at our collaborating groups, their mechanism of action was
unknown. The last part of this dissertation is focused on a preliminary evaluation of the
effect of EDL-291 on human glioma cell apoptosis machinery.
Capase 3/7 activation is one of the biochemical hallmarks of apoptosis. After
EDL-291 treatment, activity of caspase-3/7 and the amount of cleaved PARP, a product
of activated caspase-3, were increased in human glioma cell lines. The antiproliferative
effect of EDL-291 was partially reversed by the caspase-3/7 inhibitor, which confirmed
the involvement of effector caspase activation in the action of EDL-291. However,
neither the inhibitor of caspase-8 (initiator caspase for extrinsic apoptosis pathway) nor
the inhibitor of caspase-9 (initiator caspase for intrinsic pathway) reversed the apoptotic
effect of EDL-291. Therefore, the initiator caspase could be caspase-4, the initiator
caspase for the newly discovered endoplasmic reticulum (ER) stress-induced apoptosis
pathway.
Surprisingly, the antiproliferative effect of EDL-291 can be enhanced, rather than
reversed, by mitochondrial permeability transition (MPT) inhibitor decylubiquinone
(dUb). The caspase-3/7 activation after EDL-291 treatment also can be enhanced by dUb.
dUb shares structure similarity to X-linked inhibitor of apoptosis protein (XIAP) inhibitor
embelin; thus, it may also inhibit XIAP and de-inhibit caspases. Therefore, dUb could be
a candidate companion drug of EDL-291 analogs in treating glioma, which provides a
potential direction for building a mechanism-based combination chemotherapy strategy.
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